

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Escalation of care for treatment of acute asthma in children is rare in the pre-hospital setting. A retrospective observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-073029
Article Type:	Original research
Date Submitted by the Author:	21-Feb-2023
Complete List of Authors:	<p>Craig, Simon; Monash Medical Centre Clayton, Paediatric Emergency Department; Monash University Department of Paediatrics Delardes, Belinda; Ambulance Victoria; Monash University Department of Paramedicine Nehme, Ziad; Ambulance Victoria, Research & Evaluation; Monash University School of Public Health and Preventive Medicine Wilson, Catherine; Murdoch Childrens Research Institute, Emergency Medicine Research Group; PREDICT, Research Group Dalziel, Stuart; Starship Children's Health, Emergency Department; The University of Auckland Faculty of Medical and Health Sciences, Paediatrics and Surgery Nixon, Gillian; Monash University Department of Paediatrics; Monash Children's Hospital, Respiratory Medicine Powell, Colin; Sidra Medical and Research Center, Department of Emergency Medicine; Cardiff School of Health Sciences Graudins, Andis; Monash Health, Dandenong Emergency Department; Monash University Babl, Franz; Royal Childrens Hospital, Emergency Department; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Paediatrics</p>
Keywords:	Asthma < THORACIC MEDICINE, ACCIDENT & EMERGENCY MEDICINE, Paediatric A&E and ambulatory care < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Escalation of care for treatment of acute asthma in children is rare in the pre-hospital**
4 **setting.**
5
6
7
8
9

10 **Simon Craig**^{1,2,3} MBBS FACEM MPH MHPE, **Belinda Delardes**^{4,5} B Paramedic (Hons), **Ziad**
11 **Nehme**^{4,5,6} PhD, **Catherine L Wilson**³ Dip App Sci Nurs MPH Ms Evaluation and Assessment,
12 **Stuart R Dalziel**^{7,8} MBChB FRACP PhD, **Gillian M Nixon**^{1,9} MBChB MD FRACP, **Colin VE**
13 **Powell**^{10,11} MBChB DCH MRCP(UK) FRACP FRCPC MD, **Andis Gaudins**^{12,13,14} MBBS PhD
14 **FACEM FACMT, Franz E Babl**^{3,15,16,17} MD MPH DMedSc FRACP FAAP FACEP on behalf of the
15 **PREDICT Network.**
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Affiliations**

- 31
32 1. Department of Paediatrics, School of Clinical Sciences at Monash Health, Monash
33 University, Victoria, Australia.
- 34
35 2. Monash Emergency Program, Paediatric Emergency Department, Monash Medical
36 Centre, Monash Health, Victoria, Australia.
- 37
38 3. Emergency Research, Clinical Sciences, Murdoch Children's Research Institute,
39 Victoria, Australia
- 40
41 4. Ambulance Victoria, Blackburn North, Victoria, Australia
- 42
43 5. Department of Paramedicine, Monash University, Frankston, Victoria, Australia
- 44
45 6. School of Public Health and Preventive Medicine, Monash University, Melbourne,
46 Victoria, Australia
- 47
48 7. Departments of Surgery and Paediatrics: Child and Youth Health, The University of
49 Auckland, New Zealand.
- 50
51
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. Children's Emergency Department, Starship Children's Hospital, Auckland, New Zealand
9. Department of Respiratory Medicine, Monash Children's Hospital, Melbourne, Victoria, Australia.
10. Division of Population Medicine, School of Medicine, Cardiff, United Kingdom.
11. Emergency Medicine, Sidra Medicine, Doha Qatar
12. Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia.
13. Monash Emergency Program, Monash Health, Dandenong Hospital, Victoria, Australia.
14. Monash Health Clinical Toxicology and Addiction Medicine Service, Monash Health, Dandenong Hospital, Victoria, Australia.
15. Department of Emergency Medicine, The Royal Children's Hospital, Victoria, Australia.
16. Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.
17. Department of Critical Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.

Abstract 270 words (max 300)

Main text 2273 words (max 3000)

27 references (max 30)

2 tables, 2 figures, 1 box (up to 6 total)

1
2
3
4
5
6
7
8
9
10
11 Corresponding author
12

13 Prof Simon Craig
14

- 15 - Paediatric Emergency Department, Monash Medical Centre, Monash Health, Clayton,
16
17 Victoria, Australia
18
- 19 - Department of Paediatrics, Monash University, Clayton, Victoria, Australia
20
21

22 Simon.Craig@monash.edu
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Background

Asthma is a common reason for ambulance paramedic attendance for children, however, there are little data available on pre-hospital treatment patterns or outcomes. This study aimed to understand the incidence of and patterns of “escalated care” (care in addition to standard treatment with systemic corticosteroids and inhaled bronchodilators).

Methods

We conducted a retrospective observational study of state-wide ambulance service data (Ambulance Victoria in Victoria, Australia, population 6.5 million). Children aged 1-17 years and given a final diagnosis of asthma by the treating paramedics and/or treated with inhaled bronchodilators from 1 July 2019 to 30 June 2020 were analysed for demographic and clinical features, and treatment administered. We classified “escalation of care” as parenteral administration of adrenaline, or provision of respiratory support. We compared clinical, demographic and treatment administered between those receiving and not receiving escalation of care.

Results

Paramedics attended 1,572 children with acute exacerbations of asthma during the 1 year study period. Of these, 22 (1.4%) had escalated care, all receiving parenteral adrenaline.

Patients with escalated care were more likely to be older, had previously required hospital admission for asthma and had severe respiratory distress at initial assessment.

Of 1307 children with respiratory status data available, at arrival to hospital the respiratory status of children had improved overall (normal/mild respiratory distress at initial assessment 847 (64.8%), normal/mild respiratory distress at hospital arrival 1142 (87.4%), $p < 0.0001$).

Conclusion

Most children with acute exacerbations of asthma did not receive escalated therapy during their pre-hospital treatment from ambulance paramedics. Most patients were treated with inhaled bronchodilators only and clinically improved by the time they arrived in hospital.

What is already known on this topic – An acute exacerbation of asthma is a common reason for ambulance paramedic attendance for children, however, there is little data available on treatment patterns or pre-hospital outcomes.

What this study adds – Most children with acute exacerbations of asthma do not receive escalated therapy (treatment beyond systemic corticosteroids and inhaled bronchodilators) during their pre-hospital treatment from ambulance paramedics. Most patients were treated with inhaled bronchodilators only and clinically improved by the time they arrived in hospital.

How this study might affect research, practice or policy – Due to the very low incidence of treatment escalation or clinical deterioration, any comparative clinical trials to determine the superiority of one parenteral bronchodilator over another should be reserved for the in-hospital rather than pre-hospital setting.

Introduction

Asthma is a frequent reason for children to attend the emergency department (ED),^{1,2} and one of the most common reasons for paediatric hospitalization after an ED visit.³ In the USA, the rate of paediatric ED visits for asthma increased by 13.3% between 2001 and 2010,⁴ while in the United Kingdom, it is estimated that a child is admitted to hospital with an asthma attack every 20 minutes.⁵

Most children with asthma have mild or moderate exacerbations, and respond to first-line treatment with inhaled bronchodilator therapy and systemic steroids.⁶⁻⁹ However, some children with severe asthma require more intensive therapies including intravenous (IV) medications, endotracheal intubation and/or admission to intensive care.⁹⁻¹¹ Management of acute severe asthma is complicated by a number of problems, including a large number of treatment options, wide variation in self-reported and actual physician practice,¹²⁻¹⁵ and a weak evidence base.^{16,17}

Early initiation of therapy in the pre-hospital setting may abort an asthma attack and prevent further escalation on arrival to the ED. This in turn may prevent the need for more invasive treatment and potential complications or side effects of medications used in escalation. The introduction of a new treatment protocol emphasizing early use of systemic corticosteroids in a large Emergency Medical Services system was associated with reduced rates of hospitalization, less need for critical care and shortened hospital length of stay.¹⁸ Systemic corticosteroid administration has been the subject of successful improvement projects in the pre-hospital setting.¹⁹ However, a separate study identified high rates of paramedic non-compliance with pre-hospital treatment protocols recommending parenteral adrenaline for children with high-severity respiratory distress.²⁰

1
2
3 There are little data available on treatment patterns or pre-hospital outcomes for children
4 with acute asthma in the Australian setting. This study aimed to extract information from the
5 electronic medical records of Ambulance Victoria (AV), Australia, on all children treated for
6 asthma to understand the incidence of and patterns of “escalated” care (care in addition to
7 standard treatment with systemic corticosteroids and inhaled bronchodilators).
8
9
10
11
12
13
14
15
16
17

18 **Methods**

19 ***Study design***

20 This was a retrospective cohort study of all children who were either given a final diagnosis
21 of asthma by the treating AV paramedics or treated with inhaled bronchodilators from 1 July
22 2019 to 30 June 2020. The project is reported according to the Strengthening the Reporting
23 of Observational Studies in Epidemiology (STROBE) statement.²¹
24
25
26
27
28
29
30
31
32
33
34

35 ***Study setting***

36 AV is the single public emergency medical service for the state of Victoria, Australia
37 (population of 6.5 million over 227,000 square kilometres).
38
39

40 AV clinical practice guidelines²² provide recommendations for asthma management according
41 to severity (Box 1), which include: inhaled salbutamol via a pressurised metered dose inhaler
42 (pMDI) as initial treatment for mild / moderate asthma; nebulised salbutamol and
43 ipratropium reserved for severe or critical illness, or failure of moderate asthma to respond
44 to treatment after 20 minutes; corticosteroids (intravenous or oral dexamethasone) for
45 critical asthma in children and for severe and critical asthma in adults; parenteral adrenaline
46 (intramuscular, intravenous infusion or titrated boluses) for critical asthma; and assisted
47 ventilation and/or intubation for unconsciousness or respiratory arrest. Children aged 12
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 years or more are managed according to an “adult” algorithm, which has a lower threshold
4
5 for corticosteroids compared to the paediatric algorithm (recommended for all severe cases,
6
7 rather than only in critical illness) .²²
8
9

10 11 12 13 ***Selection of participants.*** 14

15 We searched the AV electronic patient care system for presentations of children aged more
16
17 than one year and less than 18 years matching the following criteria: final primary assessment
18
19 of asthma or cough or shortness of breath. We excluded children with a paramedic diagnosis
20
21 of cough or shortness of breath if they were not administered any inhaled bronchodilator
22
23 (salbutamol or ipratropium). Records of cases assessed by multiple ambulance teams during
24
25 the same incident were unified as a single paramedic attendance. Interhospital transports
26
27 and patients managed for cardiac arrest were excluded.
28
29
30
31
32
33
34

35 ***Data collection*** 36

37 Data were extracted directly from the AV medical record database into a purpose-designed
38
39 spreadsheet and analysed.
40

41 We defined “respiratory support” as the use of continuous positive airway pressure (CPAP),
42
43 bi-level positive airway pressure (BiPAP), assisted ventilation, intubation and mechanical
44
45 ventilation, or application of a bag-valve-mask device.
46
47

48 We defined “escalation” of care as parenteral administration of adrenaline, or provision of
49
50 respiratory support. Although AV protocols recommend oral (or parenteral) corticosteroids
51
52 for severe and critical asthma, corticosteroids are usually considered part of routine asthma
53
54 care (rather than reserved for critical illness). We did not include nebulised adrenaline for
55
56 suspected croup / upper airway obstruction. The case notes were reviewed and verified by a
57
58
59
60

1
2
3 second paramedic abstractor (BD) for all patients where escalation was identified through
4
5
6 electronic medical record data.
7
8
9

10 **Analysis**

11
12 Descriptive statistics were used to summarise patient characteristics, clinical features and
13
14
15 treatments administered. Non-parametric data is reported using median and interquartile
16
17
18 range (IQR), while categorical data is presented as count and percentage. We did not impute
19
20
21 any missing data.

22
23 Comparisons were made between those requiring escalation of care to those not requiring
24
25
26 escalation of care. Categorical data is compared using Chi-square test or Fisher's exact test as
27
28
29 appropriate. Non-parametric data is compared using Mann-Whitney U test.

30
31 All analyses were performed using SPSS for Windows (IBM Corp. Released 2021. IBM SPSS
32
33
34 Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp.).
35
36

37 **Patient and public involvement**

38
39
40 Patients were not involved in the design of this study.
41
42
43
44

45 **Results**

46
47 Over the study period, the service responded to 633,950 on-road emergency cases,²³ mainly
48
49
50 using advanced life support (ALS) or mobile intensive care ambulance (MICA) paramedics. We
51
52
53 identified 3,587 children who had been assessed by AV with a primary assessment diagnosis
54
55
56 of asthma, cough, or shortness of breath, 1,520 were excluded, leaving 1,572 children
57
58
59 managed by AV with asthma (figure 1).
60

1
2
3 The median age of the cohort was 6 years (IQR 4-10 years) and 888 (56.5%) were male. Most
4 (87.6%) patients had a documented past history of asthma, 115 (7.3%) had been hospitalised,
5
6 63 (4%) had required intensive care admission, and 19 (1.2%) had been intubated for a
7
8 previous asthma exacerbation. The median initial respiratory rate was 32 breaths/minute
9
10 (IQR 24 – 40 breaths/minute). Of the 1,460 patients who had initial work of breathing
11
12 documented, 978 (67.0%) had normal or mild work of breathing, and 166 (7.7%) had severe
13
14 work of breathing.
15
16
17
18
19

20 Ambulance response time was a median of 11.9 minutes (IQR 8.2 to 15.2 minutes);
21
22 paramedics were on the scene with the patient for a median of 17 minutes (IQR 12.7 to 25.1
23
24 minutes). Patients were transported by ambulance in 90% (n=1419) of attendances.
25
26

27 Paramedics administered inhaled bronchodilators in 946 (60.2%) of cases. Of those, 493
28
29 (52.1%) received salbutamol alone, 13 (1.4%) received ipratropium alone, and 440 (46.5%)
30
31 received salbutamol and ipratropium. For those receiving bronchodilators, a median (IQR) of
32
33 1 (1-2) doses was administered. Oxygen administration was documented in 306 (19.4%)
34
35 patients, most commonly by nebuliser mask, nasal cannulae, or an oxygen mask; however,
36
37 514 (32.6%) received nebulised medication, driven by oxygen. Oral corticosteroids were
38
39 administered to 141 (9.0%) patients.
40
41
42
43

44 Twenty-six records were reviewed for escalation of care; in four patients the electronic record
45
46 was incorrectly coded, due to inadvertent selection of intravenous salbutamol (used by AV
47
48 for pre-term labour) instead of nebulised salbutamol, leaving 22 (1.4%) patients with
49
50 escalated care (figure 1). Patients with escalated care were more likely to be older, had
51
52 previously required hospital admission for asthma and had severe respiratory distress at
53
54 initial assessment (Table 1). Those receiving escalated care were more likely to be treated
55
56 with inhaled bronchodilators, corticosteroids and oxygen (Table 2).
57
58
59
60

1
2
3 All patients who received escalated care received parenteral adrenaline. No patients received
4 non-invasive ventilation, assisted ventilation or intubation. Four children (aged two, fourteen,
5 sixteen and seventeen years) received an adrenaline infusion. One patient who received IM
6 adrenaline also had a bag-valve-mask applied, however, did not receive positive pressure
7 ventilation. They were a two-year-old child who had difficulty breathing and cough that was
8 not improving with salbutamol administered at home. They became unresponsive after a
9 coughing episode and bystander cardiopulmonary resuscitation was initiated. They were
10 breathing spontaneously and responsive upon initial paramedic assessment.
11
12

13 Reports of respiratory status at initial assessment and hospital arrival were available for 1307
14 (85.5%) of the cohort. On arrival to hospital the respiratory status of children had improved
15 overall (normal/mild respiratory distress at initial assessment 847 (64.8%), normal/mild
16 respiratory distress at hospital arrival 1142 (87.4%), $p < 0.0001$). One hundred and thirty-one
17 (81.2%) of the 160 children with severe respiratory distress at initial assessment had
18 improved. Of the 847 children with normal/mild respiratory distress at initial assessment, only
19 24 (2.8%) were documented as having moderate or severe respiratory distress at hospital
20 arrival; and only 9 (0.8%) of the 1146 children with normal/mild/moderate respiratory
21 distress at initial assessment were documented as having severe respiratory distress at
22 hospital arrival (Figure 2).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Discussion.**

51 This study provides a population-based state-wide assessment of pre-hospital asthma
52 management in children. Most children with acute exacerbations of asthma in Victoria,
53 Australia, did not receive escalated therapy during their pre-hospital treatment from
54
55
56
57
58
59
60

1
2
3 ambulance paramedics. Overall, the respiratory status of children improved from ambulance
4 arrival to hospital arrival in all severity categories.
5
6

7
8 The overall rate of parenteral bronchodilator (adrenaline) administration was 1.6%. No
9 patients received non-invasive ventilation, assisted ventilation or intubation, and most
10 patients were treated with inhaled bronchodilators and clinically improved by the time they
11 arrived in hospital. Those receiving escalated care were older, were more likely to have a
12 history of asthma requiring hospital admission and/or intubation and have severe respiratory
13 distress on ambulance arrival.
14
15

16
17 A recent large study described in-hospital management of acute asthma exacerbations in
18 Australia and New Zealand. In 14,029 children, there was a higher overall rates of escalated
19 therapy (7.3% overall, with 4.2% receiving parenteral bronchodilators and 4.3% respiratory
20 support).²⁴ A common indication for escalation of care is failure to adequately respond to
21 first-line therapy. The relatively low rates of treatment escalation in the pre-hospital setting
22 (1.6%) suggests that a small proportion of children are seriously ill, while most are early in
23 their treatment, and may not have had sufficient time to demonstrate improvement (or lack
24 of improvement) prior to hospital arrival.
25
26

27
28 There is little evidence to guide escalated therapy for asthma. A recent Overview of Cochrane
29 reviews of clinical trials on escalated therapy for asthma¹⁶ assessed the evidence for
30 parenteral bronchodilators, Heliox, respiratory support and inhaled magnesium. The review
31 found that the majority of comparisons involved between one and three trials and fewer than
32 100 participants, making it difficult to assess the balance between benefits and potential
33 harms. The authors were unable to make firm practice recommendations.¹⁶
34
35

36
37 There is little evidence to support intramuscular adrenaline as first-line treatment for
38 seriously ill children with asthma,²⁵ although it has a number of advantages, including ease of
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 administration and paramedic familiarity. Parenteral adrenaline is also used for anaphylaxis,
4
5 cardiac arrest, and management of hypotension, while nebulised adrenaline is used for severe
6
7 upper airway obstruction in croup. In addition, it can be easily and rapidly administered as
8
9 there is no need for dilution prior to administration, and no requirement for a prolonged
10
11 infusion.²²
12
13

14
15 Pre-hospital treatment of asthma rarely results in escalation of therapy beyond inhaled
16
17 bronchodilators and systemic corticosteroids. In addition, the use of parenteral
18
19 bronchodilators is often reserved for those who do not improve after initial inhaled
20
21 bronchodilators, and is administered relatively late in the course of an ED visit.¹⁵ Given that
22
23 most children with asthma will improve with pre-hospital treatment, and/or will not have
24
25 sufficient time to “fail to improve” with standard therapy, it appears that any comparative
26
27 clinical trials to determine the superiority of one parenteral bronchodilator over another
28
29 should be reserved for the in-hospital rather than pre-hospital setting.
30
31
32
33
34
35
36
37

38 **Limitations**

39
40 Inclusion in the study was based on a combination of paramedic diagnosis of asthma and
41
42 administration of inhaled bronchodilators. While only 89% had a diagnosis of asthma
43
44 recorded in the ambulance notes, it seems that the cohort is reflective of the asthma
45
46 population as over 87% of cases had a previous diagnosis of asthma.
47
48

49
50 Due to state-wide data collection and large numbers of patients, our study is likely to be
51
52 generalisable to other settings with similar pre-hospital care systems. However, most
53
54 ambulance cases within Victoria are concentrated in the metropolitan area of Melbourne (the
55
56 capital city), which may limit generalisability to rural and regional settings. Approximately 10%
57
58
59
60

1
2
3 of children were not transported to hospital; this is similar to the rate identified in a study of
4
5 children with seizures from the same ambulance service.²⁶
6
7

8 This study is a retrospective review of a comprehensive electronic database. We optimised
9
10 data extraction and minimised bias through the collection of variables using a piloted data
11
12 collection instrument, and application of pre-defined inclusion and exclusion criteria.^{27,28} Due
13
14 to the nature of record-keeping within the ambulance service (all cases are documented using
15
16 the electronic system), it is unlikely that any cases of escalated care were missed. As we
17
18 downloaded fields directly from the electronic medical record system, we did not
19
20 independently abstract any variables. However, we verified all instances of documented
21
22 escalation of care through consultation with a second (paramedic) reviewer and identified
23
24 four cases of misclassification. It is possible that we missed some children who were not
25
26 classified as asthma, were critically ill, not given inhaled bronchodilators and only given
27
28 parenteral adrenaline. However, this is likely to be a very small number of cases.
29
30
31
32
33
34
35
36

37 **Conclusions**

38
39 Most children with acute exacerbations of asthma did not receive escalated therapy during
40
41 their pre-hospital treatment from ambulance paramedics. Most patients were treated with
42
43 inhaled bronchodilators only and clinically improved by the time they arrived in hospital. Due
44
45 to the very low incidence of treatment escalation or clinical deterioration, any comparative
46
47 clinical trials to determine the superiority of one parenteral bronchodilator over another
48
49 should be reserved for the in-hospital rather than pre-hospital setting.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 Figure 1. Flow chart – pre-hospital management of acute asthma in children.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AV, Ambulance Victoria.

1
2
3
4
5
6 **Box 1.** Asthma severity assessment according to Ambulance Victoria Clinical Practice
7 Guidelines
8
9

10 Mild / Moderate: normal conscious state, some increased work of breathing, tachycardia,
11 speaking in phrases / sentences
12

13 Severe: agitated / distressed, markedly increased work of breathing, including accessory
14 muscle use / retraction, tachycardia, speaking in words.

15 Critical: altered conscious state, maximal work of breathing, marked tachycardia, unable to
16 talk.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographics and clinical characteristics of children treated or assessed for asthma by AV.

	Total (n=1572)	Escalation of care (n=22)	No escalation of care (n=1550)	P value (escalation vs no escalation)
Age, years, n (%)				
1-4	561 (36.3)	6 (27.3)	555 (35.8)	0.38
5-11	690 (43.9)	9 (40.9)	681 (43.9)	
12-17	321 (20.4)	7 (31.8)	314 (20.3)	
Median age, years (IQR)	6 (4-10)	10.5 (3.8 – 14.3)	6 (3.8 – 10)	0.045
Female sex, n (%)	684 (43.5)	11 (50)	877 (43.4)	0.54
Pre-existing conditions, n (%)				
Asthma	1377 (87.6)	20 (90.9)	1357 (87.5)	0.64
Requiring hospital admission	115 (7.3)	5 (22.7)	110 (7.1)	0.005
Requiring intensive care	63 (4)	1 (4.5)	62 (4)	0.89
Requiring intubation	19 (1.2)	1 (4.5)	18 (1.2)	0.15
With cardiac / respiratory arrest	5 (0.3)	0 (0)	5 (0.3)	0.79
Other respiratory illness				
Croup	94 (6)	1 (4.5)	93 (6)	0.78
Bronchiolitis	80 (5.1)	1 (4.5)	79 (5.1)	0.91
Pneumonia	44 (2.8)	1 (4.5)	43 (2.8)	0.62
Chest infection	32 (2)	1 (4.5)	31 (2)	0.40
Other	8 (0.5)	0 (0)	8 (0.5)	0.64
Initial physiological parameters				
Respiratory rate (breaths/minute), median (IQR)	32 (24 – 40)	35.5 (28 – 48.5)	32 (24 – 40)	0.09
Pulse rate (beats/minute), median (IQR)	130 (112 – 146)	134.5 (120 – 150.5)	130 (112 – 146)	0.24
Initial respiratory status, n (%)				
Normal	615 (39.1)	3 (13.6)	612 (39.5)	<0.001
Mild respiratory distress	363 (23.1)	1 (4.5)	362 (23.4)	
Moderate respiratory distress	315 (20)	2 (9.1)	313 (20.2)	
Severe respiratory distress	166 (10.6)	16 (72.7)	150 (9.7)	
Depressed respirations	1 (0.1)	0 (0)	1 (0.1)	

1
2
3 All P values calculated using Chi-Square tests, except for continuous variables where Mann-
4 Whitney U tests* were used.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 2. Treatment provided by AV paramedics.

	Total (n=1572)	Escalation of care (n=22)	No escalation of care (n=1550)	P value (escalation vs no escalation)
Respiratory support, n(%)				
Bag-valve-mask applied	1 (0.1)	1 (4.5)	0 (0)	<0.001
Oxygen delivery				
Nasal cannulae	46 (2.9)	4 (18.2)	42 (2.7)	<0.001
Nebuliser mask	258 (16.4)	10 (45.5)	248 (16)	<0.001
Oxygen mask	48 (3.1)	0 (0)	48 (3.1)	0.40
Non-rebreather mask	8 (0.5)	0 (0)	8 (0.5)	0.74
Other oxygen therapy (not otherwise specified)	2 (0.1)	0 (0)	2 (0.1)	0.87
Parenteral bronchodilator				
Adrenaline IM injection	20 (1.3)	20 (90.9)	0 (0)	<0.001
Adrenaline infusion	4 (0.3)	4 (18.2)	0 (0)	<0.001
Dexamethasone				
IV injection	25 (1.6)	4 (18.2)	21 (1.4)	<0.001
Oral	141 (9)	11 (50)	130 (8.4)	<0.001
Inhaled bronchodilator				
Any inhaled bronchodilator	946 (60.2)	21 (95.5)	925 (59.7)	<0.001
Any Ipratropium bromide nebulisation	453 (28.8)	17 (77.3)	436 (28.1)	<0.001
Any Salbutamol pMDI	465 (29.6)	3 (13.6)	462 (29.8)	0.10
Any Salbutamol nebulisation	514 (32.6)	20 (90.9)	493 (31.8)	<0.001
Single dose of inhaled salbutamol	348 (22.1)	3 (13.6)	345 (22.3)	
Single dose of inhaled ipratropium bromide	13 (0.8)	1 (4.5)	12 (0.8)	
Single dose of inhaled salbutamol and single dose of inhaled ipratropium bromide	280 (17.8)	6 (27.3)	274 (17.7)	
Two doses of inhaled salbutamol alone	114 (7.3)	1 (4.5)	113 (7.3)	

Two doses of inhaled salbutamol and at least one dose of ipratropium bromide	112 (7.1)	3 (13.6)	109 (7)	
Three or more doses of inhaled salbutamol alone	31 (2.0)	0 (0)	31 (2)	
Three or more doses of inhaled salbutamol and at least one dose of ipratropium bromide	49 (3.1)	7 (31.8)	41 (2.6)	
Total instances of inhaled bronchodilator administration, median (IQR)	1 (0-2)	2 (1.8 – 4)	1 (0 – 2)	<0.001
Intravenous access				
Intravenous access attempt	39 (2.5)	7 (31.8)	32 (2.1)	<0.001
Successful IV attempt	34 (2.2)	7 (31.8)	27 (1.7)	<0.001

No patients received any of: BIPAP, manual ventilation, mechanical ventilation, IV salbutamol infusion, IM dexamethasone.


1
2
3 **Figure 2.** Initial and final respiratory status documented by AV paramedics.
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Note: 111 patients missing initial respiratory status, and 265 missing final respiratory status.


References

1. Alpern ER, Stanley RM, Gorelick MH, et al. Epidemiology of a pediatric emergency medicine research network: the PECARN Core Data Project. *Pediatric emergency care* 2006; **22**(10): 689-99.
2. Acworth J, Babl F, Borland M, et al. Patterns of presentation to the Australian and New Zealand Paediatric Emergency Research Network. *Emerg Med Australas* 2009; **21**(1): 59-66.
3. Weiss AJ, Wier LM, Stocks C, Blanchard J. Overview of Emergency Department Visits in the United States, 2011: Statistical Brief #174. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.
4. Nath JB, Hsia RY. Children's emergency department use for asthma, 2001-2010. *Academic pediatrics* 2015; **15**(2): 225-30.
5. Kantor DB, Phipatanakul W. Intravenous beta agonists and severe pediatric asthma exacerbation: time for a closer look at terbutaline? *Ann Allergy Asthma Immunol* 2014; **112**(3): 187.
6. Giordano K, Rodriguez E, Green N, et al. Pulmonary Function Tests in Emergency Department Pediatric Patients with Acute Wheezing/Asthma Exacerbation. *Pulmonary Medicine* 2012; **2012**: 724139.
7. Kelly AM, Kerr D, Powell C. Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma? *Respir Med* 2004; **98**(8): 777-81.
8. Powell CV, Kelly AM, Kerr D. Lack of agreement in classification of the severity of acute asthma between emergency physician assessment and classification using the National Asthma Council Australia guidelines (1998). *Emergency medicine (Fremantle, WA)* 2003; **15**(1): 49-53.
9. O'Connor MG, Saville BR, Hartert TV, Arnold DH. Treatment Variability of Asthma Exacerbations in a Pediatric Emergency Department Using a Severity-Based Management Protocol. *Clinical pediatrics* 2014; **53**(13): 1288-90.
10. Biagini Myers JM, Simmons JM, Kercksmar CM, et al. Heterogeneity in asthma care in a statewide collaborative: the Ohio Pediatric Asthma Repository. *Pediatrics* 2015; **135**(2): 271-9.
11. Morris I, Lyttle MD, O'Sullivan R, Sargant N, Doull IJ, Powell CV. Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland? *Thorax* 2015; **70**(1): 88-91.
12. Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. *BMJ Open Respir Res* 2022; **9**(1).
13. Monteverde-Fernandez N, Diaz-Rubio F, Vásquez-Hoyos P, Rotta AT, González-Dambruskas S. Variability in care for children with severe acute asthma in Latin America. *Pediatr Pulmonol* 2021; **56**(2): 384-91.
14. Kalburgi S, Halley T. High-Flow Nasal Cannula Use Outside of the ICU Setting. *Pediatrics* 2020; **146**(5).
15. Johnson MD, Zorc JJ, Nelson DS, et al. Intravenous Magnesium in Asthma Pharmacotherapy: Variability in Use in the PECARN Registry. *J Pediatr* 2020; **220**: 165-74.e2.

16. Craig SS, Dalziel SR, Powell CV, Graudins A, Babl FE, Lunny C. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2020; **8**: Cd012977.
17. Gray CS, Powell CVE, Babl FE, Dalziel SR, Craig S. Variability of outcome measures in trials of intravenous therapy in acute severe paediatric asthma: a systematic review. *Emerg Med J* 2019; **36**(4): 225-30.
18. Nassif A, Ostermayer DG, Hoang KB, Claiborne MK, Camp EA, Shah MI. Implementation of a Prehospital Protocol Change For Asthmatic Children. *Prehosp Emerg Care* 2018; **22**(4): 457-65.
19. Riney LC, Schwartz H, Murtagh Kurowski E, Collett L, Florin TA. Improving Administration of Prehospital Corticosteroids for Pediatric Asthma. *Pediatr Qual Saf* 2021; **6**(3): e410.
20. Cheetham AL, Navanandan N, Leonard J, Spaur K, Markowitz G, Adalgais KM. Impact of prehospital pediatric asthma management protocol adherence on clinical outcomes. *J Asthma* 2022; **59**(5): 937-45.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; **147**(8): 573-7.
22. Ambulance Victoria. Clinical Practice Guidelines for Ambulance and MICA Paramedics. January 2018. Ambulance Victoria, Doncaster.
[Online resource: Available from: <https://www.ambulance.vic.gov.au/wp-content/uploads/2019/07/Clinical-Practice-Guidelines-2018-Edition-1.9-1.pdf> Accessed 15/9/2022].
23. Ambulance Victoria Annual report 2019-20. Ambulance Victoria, Melbourne. 2020.
[Online resource. Available from: <https://www.ambulance.vic.gov.au/about-us/our-performance/> Accessed 15/9/2022].
24. Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. *BMJ Open Respir Res.* 2022 Mar;9(1):e001137. .
25. Hasegawa K, Craig SS, Teach SJ, Camargo CA Jr. Management of Asthma Exacerbations in the Emergency Department. *J Allergy Clin Immunol Pract.* 2020 Dec 31:S2213-2198(20)31399-4. .
26. Pfeiffer CK, Smith K, Bernard S, et al. Prehospital benzodiazepine use and need for respiratory support in paediatric seizures. *Emerg Med J* 2022; **39**(8): 608-15.
27. Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta DC, Steiner J. Chart reviews in emergency medicine research: Where are the methods? *Ann Emerg Med* 1996; **27**(3): 305-8.
28. Kaji AH, Schriger D, Green S. Looking through the retrospectroscope: reducing bias in emergency medicine chart review studies. *Ann Emerg Med* 2014; **64**(3): 292-8.



152x205mm (300 x 300 DPI)



1328x1387mm (72 x 72 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract YES – see title.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Structured abstract provided
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 7
Objectives	3	State specific objectives, including any prespecified hypotheses Page 8
Methods		
Study design	4	Present key elements of study design early in the paper Page 8 – (“study design” section)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 8-9 (“study setting” section)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case Page 9 (“selection of participants” section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 9-10 (“data collection” section)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 9-10 (“data collection” section)
Bias	9	Describe any efforts to address potential sources of bias Page 10 (end of “data collection” section)
Study size	10	Explain how the study size was arrived at Page 10 (“analysis” section)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 10 (“analysis” section)

Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i>—If applicable, explain how loss to follow-up was addressed <i>Case-control study</i>—If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i>—If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p> <p>Page 10 (“analysis” section)</p>
Results		
Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 10-11 (“results” section)</p> <p>(b) Give reasons for non-participation at each stage Page 10-11 (“results” section)</p> <p>(c) Consider use of a flow diagram – See figure 1</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 10-11 (“results” section) and table 1</p> <p>(b) Indicate number of participants with missing data for each variable of interest Not applicable (no missing data)</p> <p>(c) <i>Cohort study</i>—Summarise follow-up time (eg, average and total amount) Not applicable (no patient follow-up)</p>
Outcome data	15*	<p><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</p> <p><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</p> <p><i>Cross-sectional study</i>—Report numbers of outcome events or summary measures Table 2, Figure 2 and results (page 10-12)</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Table 2, Figure 2 and results (page 10-12)</p>
Other analyses	17	<p>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</p> <p>Not applicable. No subgroup analyses performed</p>
Discussion		
Key results	18	<p>Summarise key results with reference to study objectives Page 13-14</p>
Limitations	19	<p>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 14-15</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
----------------	----	--

Page 13-15

Generalisability	21	Discuss the generalisability (external validity) of the study results
------------------	----	---

Page 13-15

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	---

Funding disclosures provided

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Acute paediatric asthma treatment in the pre-hospital setting: a retrospective observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-073029.R1
Article Type:	Original research
Date Submitted by the Author:	25-Apr-2023
Complete List of Authors:	Craig, Simon; Monash Medical Centre Clayton, Paediatric Emergency Department; Monash University Department of Paediatrics Delardes, Belinda; Ambulance Victoria; Monash University Department of Paramedicine Nehme, Ziad; Ambulance Victoria, Research & Evaluation; Monash University School of Public Health and Preventive Medicine Wilson, Catherine; Murdoch Childrens Research Institute, Emergency Medicine Research Group; PREDICT, Research Group Dalziel, Stuart; Starship Children's Health, Emergency Department; The University of Auckland Faculty of Medical and Health Sciences, Paediatrics and Surgery Nixon, Gillian; Monash University Department of Paediatrics; Monash Children's Hospital, Respiratory Medicine Powell, Colin; Sidra Medical and Research Center, Department of Emergency Medicine; Cardiff School of Health Sciences Graudins, Andis; Monash Health, Dandenong Emergency Department; Monash University Babl, Franz; Royal Childrens Hospital, Emergency Department; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Paediatrics
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Emergency medicine
Keywords:	Asthma < THORACIC MEDICINE, ACCIDENT & EMERGENCY MEDICINE, Paediatric A&E and ambulatory care < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Acute paediatric asthma treatment in the pre-hospital setting: a retrospective**
4 **observational study.**
5
6
7
8
9

10 **Simon Craig**^{1,2,3} MBBS FACEM MPH MHPE, **Belinda Delardes**^{4,5} B Paramedic (Hons), **Ziad**
11 **Nehme**^{4,5,6} PhD, **Catherine L Wilson**³ Dip App Sci Nurs MPH Ms Evaluation and Assessment,
12 **Stuart R Dalziel**^{7,8} MBChB FRACP PhD, **Gillian M Nixon**^{1,9} MBChB MD FRACP, **Colin VE**
13 **Powell**^{10,11} MBChB DCH MRCP(UK) FRACP FRCPC MD, **Andis Gaudins**^{12,13,14} MBBS PhD
14 FACEM FACMT, **Franz E Babl**^{3,15,16,17} MD MPH DMedSc FRACP FAAP FACEP on behalf of the
15 PREDICT Network.
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Affiliations**

- 31
32 1. Department of Paediatrics, School of Clinical Sciences at Monash Health, Monash
33 University, Victoria, Australia.
34
35 2. Monash Emergency Program, Paediatric Emergency Department, Monash Medical
36 Centre, Monash Health, Victoria, Australia.
37
38 3. Emergency Research, Clinical Sciences, Murdoch Children's Research Institute,
39 Victoria, Australia
40
41 4. Ambulance Victoria, Blackburn North, Victoria, Australia
42
43 5. Department of Paramedicine, Monash University, Frankston, Victoria, Australia
44
45 6. School of Public Health and Preventive Medicine, Monash University, Melbourne,
46 Victoria, Australia
47
48 7. Departments of Surgery and Paediatrics: Child and Youth Health, The University of
49 Auckland, New Zealand.
50
51
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. Children's Emergency Department, Starship Children's Hospital, Auckland, New Zealand
9. Department of Respiratory Medicine, Monash Children's Hospital, Melbourne, Victoria, Australia.
10. Division of Population Medicine, School of Medicine, Cardiff, United Kingdom.
11. Emergency Medicine, Sidra Medicine, Doha Qatar
12. Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia.
13. Monash Emergency Program, Monash Health, Dandenong Hospital, Victoria, Australia.
14. Monash Health Clinical Toxicology and Addiction Medicine Service, Monash Health, Dandenong Hospital, Victoria, Australia.
15. Department of Emergency Medicine, The Royal Children's Hospital, Victoria, Australia.
16. Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.
17. Department of Critical Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.

Abstract 238 words (max 300)

Main text 2398 words (max 3000)

27 references (max 30)

2 tables, 2 figures, 1 box (up to 6 total). One supplementary online table.

1
2
3
4
5
6
7
8
9
10 Corresponding author
11
12

13 Prof Simon Craig
14

- 15 - Paediatric Emergency Department, Monash Medical Centre, Monash Health, Clayton,
16
17 Victoria, Australia
18
- 19 - Department of Paediatrics, Monash University, Clayton, Victoria, Australia
20
21

22 Simon.Craig@monash.edu
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Objectives:** To describe the incidence of and patterns of “escalated care” (care in addition to
4 standard treatment with systemic corticosteroids and inhaled bronchodilators) for children
5 receiving pre-hospital treatment for asthma.
6
7
8
9

10
11
12
13 **Design:** Retrospective observational study
14
15

16
17
18 **Setting:** State-wide ambulance service data (Ambulance Victoria in Victoria, Australia,
19 population 6.5 million)
20
21
22

23
24
25 **Participants:** Children aged 1-17 years and given a final diagnosis of asthma by the treating
26 paramedics and/or treated with inhaled bronchodilators from 1 July 2019 to 30 June 2020.
27
28
29

30
31
32 **Primary and secondary outcome measures:** We classified “escalation of care” as parenteral
33 administration of adrenaline, or provision of respiratory support. We compared clinical,
34 demographic and treatments administered between those receiving and not receiving
35 escalation of care.
36
37
38
39
40
41
42
43
44

45 **Results:** Paramedics attended 1,572 children with acute exacerbations of asthma during the
46 1-year study period. Of these, 22 (1.4%) had escalated care, all receiving parenteral
47 adrenaline. Patients with escalated care were more likely to be older, had previously required
48 hospital admission for asthma and had severe respiratory distress at initial assessment.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3
4
5
6 **Conclusions:** Most children with acute exacerbations of asthma did not receive escalated
7
8 therapy during their pre-hospital treatment from ambulance paramedics. Most patients were
9
10 treated with inhaled bronchodilators only and clinically improved by the time they arrived in
11
12 hospital.
13
14
15
16
17
18
19
20
21
22

23 **Strengths and limitations of this study**

- 24 - Highly generalisable, with the use of a comprehensive electronic state-wide
25 ambulance database.
26
- 27 - Most ambulance cases were concentrated in metropolitan regions; this may limit
28 generalisability to rural and regional settings.
29
- 30 - Bias was minimised by direct download from electronic medical record, rather than
31 abstraction by reviewers.
32
- 33 - It is possible that a small number of critically ill cases were misclassified due to an
34 ambulance diagnosis other than asthma.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Asthma is a frequent reason for children to attend the emergency department (ED),^{1,2} and one of the most common reasons for paediatric hospitalization after an ED visit.³ In the USA, the rate of paediatric ED visits for asthma increased by 13.3% between 2001 and 2010,⁴ while in the United Kingdom, it is estimated that a child is admitted to hospital with an asthma attack every 20 minutes.⁵

Most children with asthma have mild or moderate exacerbations, and respond to first-line treatment with inhaled bronchodilator therapy and systemic steroids.⁶⁻⁹ However, some children with severe asthma require more intensive therapies including intravenous (IV) medications, endotracheal intubation and/or admission to intensive care.⁹⁻¹¹ Management of acute severe asthma is complicated by a number of problems, including a large number of treatment options, wide variation in self-reported and actual physician practice,¹²⁻¹⁵ and a weak evidence base.^{16,17}

Early initiation of therapy in the pre-hospital setting may abort an asthma attack and prevent further escalation on arrival to the ED. This in turn may prevent the need for more invasive treatment and potential complications or side effects of medications used in escalation. The introduction of a new treatment protocol emphasizing early use of systemic corticosteroids in a large Emergency Medical Services system was associated with reduced rates of hospitalization, less need for critical care and shortened hospital length of stay.¹⁸ Systemic corticosteroid administration has been the subject of successful improvement projects in the pre-hospital setting.¹⁹ However, a separate study identified high rates of paramedic non-compliance with pre-hospital treatment protocols recommending parenteral adrenaline for children with high-severity respiratory distress.²⁰

1
2
3 There are little data available on treatment patterns or pre-hospital outcomes for children
4 with acute asthma in the Australian setting. This study aimed to extract information from the
5 electronic medical records of Ambulance Victoria (AV), Australia, on all children treated for
6 asthma to understand the incidence of and patterns of “escalated” care (care in addition to
7 standard treatment with systemic corticosteroids and inhaled bronchodilators).
8
9
10
11
12
13
14
15
16
17

18 **Methods**

19 ***Study design***

20
21 This was a retrospective cohort study of all children who were either given a final diagnosis
22 of asthma by the treating AV paramedics or treated with inhaled bronchodilators from 1 July
23 2019 to 30 June 2020. The project is reported according to the Strengthening the Reporting
24 of Observational Studies in Epidemiology (STROBE) statement.²¹ The study was approved by
25 the Royal Children’s Hospital Research Ethics and Governance Office, Melbourne, Australia
26 (60707) and the Ambulance Victoria Research Governance Committee, Melbourne, Australia.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 ***Study setting***

41
42 AV is the single public emergency medical service for the state of Victoria, Australia
43 (population of 6.5 million over 227,000 square kilometres).
44
45

46
47 AV clinical practice guidelines²² provide recommendations for asthma management according
48 to severity (Box 1), which include: inhaled salbutamol via a pressurised metered dose inhaler
49 (pMDI) as initial treatment for mild / moderate asthma; nebulised salbutamol and
50 ipratropium reserved for severe or critical illness, or failure of moderate asthma to respond
51 to treatment after 20 minutes; corticosteroids (intravenous or oral dexamethasone) for
52 critical asthma in children and for severe and critical asthma in adults; parenteral adrenaline
53
54
55
56
57
58
59
60

1
2
3 (intramuscular, intravenous infusion or titrated boluses) for critical asthma; and assisted
4
5 ventilation and/or intubation for unconsciousness or respiratory arrest. Children aged 12
6
7 years or more are managed according to an “adult” algorithm, which has a lower threshold
8
9 for corticosteroids compared to the paediatric algorithm (recommended for all severe cases,
10
11 rather than only in critical illness) .²²
12
13
14
15
16
17

18 ***Selection of participants.***

19
20 We searched the AV electronic patient care system for presentations of children aged more
21
22 than one year and less than 18 years matching the following criteria: final primary assessment
23
24 of asthma or cough or shortness of breath. We excluded children with a paramedic diagnosis
25
26 of cough or shortness of breath if they were not administered any inhaled bronchodilator
27
28 (salbutamol or ipratropium). Records of cases assessed by multiple ambulance teams during
29
30 the same incident were unified as a single paramedic attendance. Interhospital transports
31
32 and patients managed for cardiac arrest were excluded.
33
34
35
36
37
38
39

40 ***Data collection***

41
42 Data were extracted directly from the AV medical record database into a purpose-designed
43
44 spreadsheet and analysed. Exact medication doses were not extracted, as treatment is highly
45
46 protocolised (Box 1).
47
48

49 We defined “respiratory support” as the use of continuous positive airway pressure (CPAP),
50
51 bi-level positive airway pressure (BiPAP), assisted ventilation, intubation and mechanical
52
53 ventilation, or application of a bag-valve-mask device.
54
55

56 We defined “escalation” of care as parenteral administration of adrenaline, or provision of
57
58 respiratory support. Although AV protocols recommend oral (or parenteral) corticosteroids
59
60

1
2
3 for severe and critical asthma, corticosteroids are usually considered part of routine asthma
4 care (rather than reserved for critical illness). We did not include nebulised adrenaline for
5 suspected croup / upper airway obstruction. The case notes were reviewed and verified by a
6 second paramedic abstractor (BD) for all patients where escalation was identified through
7 electronic medical record data.
8
9
10
11
12
13
14
15
16
17

18 ***Analysis***

19
20 Descriptive statistics were used to summarise patient characteristics, clinical features and
21 treatments administered. Non-parametric data is reported using median and interquartile
22 range (IQR), while categorical data is presented as count and percentage. We did not impute
23 any missing data.
24
25
26
27
28

29
30 Comparisons were made between those requiring escalation of care to those not requiring
31 escalation of care. Categorical data is compared using Chi-square test or Fisher's exact test as
32 appropriate. Non-parametric data is compared using Mann-Whitney U test.
33
34
35
36

37 All analyses were performed using SPSS for Windows (IBM Corp. Released 2021. IBM SPSS
38 Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp.).
39
40
41
42
43
44

45 ***Patient and public involvement***

46
47 Patients were not involved in the design of this study.
48
49
50
51

52 **Results**

53
54 Over the study period, the service responded to 633,950 on-road emergency cases,²³ mainly
55 using advanced life support (ALS) or mobile intensive care ambulance (MICA) paramedics. We
56 identified 3,587 children who had been assessed by AV with a primary assessment diagnosis
57
58
59
60

1
2
3 of asthma, cough, or shortness of breath, 1,520 were excluded, leaving 1,572 children
4 managed by AV with asthma (figure 1).
5
6

7
8 The median age of the cohort was 6 years (IQR 4-10 years) and 888 (56.5%) were male. Most
9
10 (87.6%) patients had a documented past history of asthma, 115 (7.3%) had been hospitalised,
11
12 63 (4%) had required intensive care admission, and 19 (1.2%) had been intubated for a
13
14 previous asthma exacerbation. Information on usual asthma medications was not available.
15
16 The median initial respiratory rate was 32 breaths/minute (IQR 24 – 40 breaths/minute). Of
17
18 the 1,460 patients who had initial work of breathing documented, 978 (67.0%) had normal or
19
20 mild work of breathing, and 166 (7.7%) had severe work of breathing.
21
22
23

24
25 Ambulance response time was a median of 11.9 minutes (IQR 8.2 to 15.2 minutes);
26
27 paramedics were on the scene with the patient for a median of 17 minutes (IQR 12.7 to 25.1
28
29 minutes). Patients were transported by ambulance in 90% (n=1419) of attendances.
30
31

32
33 Paramedics administered inhaled bronchodilators in 946 (60.2%) of cases. Of those, 493
34
35 (52.1%) received salbutamol alone, 13 (1.4%) received ipratropium alone, and 440 (46.5%)
36
37 received salbutamol and ipratropium. For those receiving bronchodilators, a median (IQR) of
38
39 1 (1-2) administrations were recorded. Oxygen administration was documented in 306
40
41 (19.4%) patients, most commonly by nebuliser mask, nasal cannulae, or an oxygen mask;
42
43 however, 514 (32.6%) received nebulised medication, driven by oxygen. Oral corticosteroids
44
45 were administered to 141 (9.0%) patients.
46
47
48

49
50 Twenty-six records were reviewed for escalation of care; in four patients the electronic record
51
52 was incorrectly coded, due to inadvertent selection of intravenous salbutamol (used by AV
53
54 for pre-term labour) instead of nebulised salbutamol, leaving 22 (1.4%) patients with
55
56 escalated care (figure 1). Patients with escalated care were more likely to be older, had
57
58 previously required hospital admission for asthma and had severe respiratory distress at
59
60

1
2
3 initial assessment (Table 1). Those receiving escalated care were more likely to be treated
4
5 with inhaled bronchodilators, corticosteroids and oxygen (Table 2). With increasing severity
6
7 of illness, children were more likely to be administered nebulised salbutamol, less likely to be
8
9 administered salbutamol by a pMDI, more likely to receive ipratropium and more likely to
10
11 receive systemic corticosteroids (Supplementary Online Table).
12
13

14
15 All patients who received escalated care received parenteral adrenaline. No patients received
16
17 non-invasive ventilation, assisted ventilation or intubation. Four children (aged two, fourteen,
18
19 sixteen and seventeen years) received an adrenaline infusion. One patient who received IM
20
21 adrenaline also had a bag-valve-mask applied, however, did not receive positive pressure
22
23 ventilation. They were a two-year-old child who had difficulty breathing and cough that was
24
25 not improving with salbutamol administered at home. They became unresponsive after a
26
27 coughing episode and bystander cardiopulmonary resuscitation was initiated. They were
28
29 breathing spontaneously and responsive upon initial paramedic assessment.
30
31
32
33

34
35 Reports of respiratory status at initial assessment and hospital arrival were available for 1307
36
37 (85.5%) of the cohort. On arrival to hospital the respiratory status of children had improved
38
39 overall (normal/mild respiratory distress at initial assessment 847 (64.8%), normal/mild
40
41 respiratory distress at hospital arrival 1142 (87.4%), $p < 0.0001$). One hundred and thirty-one
42
43 (81.2%) of the 160 children with severe respiratory distress at initial assessment had
44
45 improved. Of the 847 children with normal/mild respiratory distress at initial assessment, only
46
47 24 (2.8%) were documented as having moderate or severe respiratory distress at hospital
48
49 arrival; and only 9 (0.8%) of the 1146 children with normal/mild/moderate respiratory
50
51 distress at initial assessment were documented as having severe respiratory distress at
52
53 hospital arrival (Figure 2).
54
55
56
57
58
59
60

Discussion.

This study provides a population-based state-wide assessment of pre-hospital asthma management in children. Most children with acute exacerbations of asthma in Victoria, Australia, did not receive escalated therapy during their pre-hospital treatment from ambulance paramedics. Although more than 60% had either mild or no respiratory distress, over 90% of all patients were transported to hospital. Overall, the respiratory status of children improved from ambulance arrival to hospital arrival in all severity categories.

The overall rate of parenteral bronchodilator (adrenaline) administration was 1.6%. No patients received non-invasive ventilation, assisted ventilation or intubation, and most patients were treated with inhaled bronchodilators and clinically improved by the time they arrived in hospital. Those receiving escalated care were older, were more likely to have a history of asthma requiring hospital admission and/or intubation and have severe respiratory distress on ambulance arrival.

A recent large study described in-hospital management of acute asthma exacerbations in Australia and New Zealand. In 14,029 children, there was a higher overall rates of escalated therapy (7.3% overall, with 4.2% receiving parenteral bronchodilators and 4.3% respiratory support).²⁴ A common indication for escalation of care is failure to adequately respond to first-line therapy. The relatively low rates of treatment escalation in the pre-hospital setting (1.6%) suggests that a small proportion of children are seriously ill, while most are early in their treatment, and may not have had sufficient time to demonstrate improvement (or lack of improvement) prior to hospital arrival.

There is little evidence to guide escalated therapy for asthma. A recent Overview of Cochrane reviews of clinical trials on escalated therapy for asthma¹⁶ assessed the evidence for parenteral bronchodilators, Heliox, respiratory support and inhaled magnesium. The review

1
2
3 found that the majority of comparisons involved between one and three trials and fewer than
4
5 100 participants, making it difficult to assess the balance between benefits and potential
6
7 harms. The authors were unable to make firm practice recommendations.¹⁶
8
9

10 There is little evidence to support intramuscular adrenaline as first-line treatment for
11
12 seriously ill children with asthma,²⁵ although it has a number of advantages, including ease of
13
14 administration and paramedic familiarity. Parenteral adrenaline is also used for anaphylaxis,
15
16 cardiac arrest, and management of hypotension, while nebulised adrenaline is used for severe
17
18 upper airway obstruction in croup. In addition, it can be easily and rapidly administered as
19
20 there is no need for dilution prior to administration, and no requirement for a prolonged
21
22 infusion.²²
23
24
25
26

27 Pre-hospital treatment of asthma rarely results in escalation of therapy beyond inhaled
28
29 bronchodilators and systemic corticosteroids. In addition, the use of parenteral
30
31 bronchodilators is often reserved for those who do not improve after initial inhaled
32
33 bronchodilators, and is administered relatively late in the course of an ED visit.¹⁵ Given that
34
35 most children with asthma will improve with pre-hospital treatment, and/or will not have
36
37 sufficient time to “fail to improve” with standard therapy, it appears that any comparative
38
39 clinical trials to determine the superiority of one parenteral bronchodilator over another
40
41 should be reserved for the in-hospital rather than pre-hospital setting.
42
43
44
45
46
47
48
49

50 **Limitations**

51
52 Inclusion in the study was based on a combination of paramedic diagnosis of asthma and
53
54 administration of inhaled bronchodilators. While only 89% had a diagnosis of asthma
55
56 recorded in the ambulance notes, it seems that the cohort is reflective of the asthma
57
58 population as over 87% of cases had a previous diagnosis of asthma.
59
60

1
2
3 Due to state-wide data collection and large numbers of patients, our study is likely to be
4 generalisable to other settings with similar pre-hospital care systems. However, most
5
6 generalisable to other settings with similar pre-hospital care systems. However, most
7
8 ambulance cases within Victoria are concentrated in the metropolitan area of Melbourne (the
9
10 capital city), which may limit generalisability to rural and regional settings. Approximately 10%
11
12 of children were not transported to hospital; this is similar to the rate identified in a study of
13
14 children with seizures from the same ambulance service.²⁶
15
16

17
18 This study is a retrospective review of a comprehensive electronic database. We optimised
19
20 data extraction and minimised bias through the collection of variables using a piloted data
21
22 collection instrument, and application of pre-defined inclusion and exclusion criteria.^{27,28} Due
23
24 to the nature of record-keeping within the ambulance service (all cases are documented using
25
26 the electronic system), it is unlikely that any cases of escalated care were missed. As we
27
28 downloaded fields directly from the electronic medical record system, we did not
29
30 independently abstract any variables. However, we verified all instances of documented
31
32 escalation of care through consultation with a second (paramedic) reviewer and identified
33
34 four cases of misclassification. It is possible that we missed some children who were not
35
36 classified as asthma, were critically ill, not given inhaled bronchodilators and only given
37
38 parenteral adrenaline. However, this is likely to be a very small number of cases. There was
39
40 some missing data on final observations on arrival to hospital, however, this was not a primary
41
42 objective of our study.
43
44
45
46
47
48
49
50
51

52 **Conclusions**

53
54 Most children with acute exacerbations of asthma did not receive escalated therapy during
55
56 their pre-hospital treatment from ambulance paramedics. Most patients were treated with
57
58 inhaled bronchodilators only and clinically improved by the time they arrived in hospital. Due
59
60

1
2
3 to the very low incidence of treatment escalation or clinical deterioration, any comparative
4
5 clinical trials to determine the superiority of one parenteral bronchodilator over another
6
7
8 should be reserved for the in-hospital rather than pre-hospital setting.
9
10
11
12
13
14

15 **Funding**

16
17
18 This work is supported by the NHMRC Centre of Research Excellence in Paediatric Emergency
19
20 Medicine (GNT1171228), Canberra, Australia. SC's contribution was funded by the Thoracic
21
22 Society of Australia and New Zealand and National Asthma Council Fellowship, 2020 and the
23
24 Australasian College for Emergency Medicine Foundation Al Spilman Early Career Research
25
26 Grant 2017. SRDs time was in part funded by Cure Kids New Zealand. FEB's time was funded
27
28 by an NHMRC Investigator Leadership grant and the Royal Children's Hospital Foundation,
29
30 Parkville, Australia.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Figure 1. Flow chart – pre-hospital management of acute asthma in children.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AV, Ambulance Victoria.

For peer review only

1
2
3
4
5
6 **Box 1.** Asthma severity assessment and treatment according to Ambulance Victoria Clinical
7 Practice Guidelines
8
9

10 **Mild / Moderate:** normal conscious state, some increased work of breathing, tachycardia,
11 speaking in phrases / sentences
12

- 13 - Salbutamol pMDI and spacer:
 - 14 ○ 6 or more years: 4-12 doses
 - 15 ○ 2-5 years: 2-6 doses

16
17
18 **Severe:** agitated / distressed, markedly increased work of breathing, including accessory
19 muscle use / retraction, tachycardia, speaking in words.
20

- 21 - Salbutamol nebulised (repeated at 20 minutes if required)
 - 22 ○ 2-4 years: 2.5 mg
 - 23 ○ 5-11 years: 2.5 - 5 mg
- 24 - Ipratropium bromide nebulised 250 mcg

25
26
27
28 **Critical:** altered conscious state, maximal work of breathing, marked tachycardia, unable to
29 talk.
30

- 31 - Salbutamol nebulised 10 mg (repeated at 5 minutes if required)
 - 32 - Ipratropium bromide nebulised 250 mcg
 - 33 - Adrenaline 10 mcg/kg IM (repeated at 5 minutes if required)
 - 34 - Dexamethasone 0.6 mg/kg IV or oral (max 12 mg)
 - 35 - Adrenaline IV boluses and infusion (for Mobile Intensive Care Paramedics)
- 36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographics and clinical characteristics of children treated or assessed for asthma by AV.

	Total (n=1572)	Escalation of care (n=22)	No escalation of care (n=1550)	P value (escalation vs no escalation)
Age, years, n (%)				
1-4	561 (36.3)	6 (27.3)	555 (35.8)	0.38
5-11	690 (43.9)	9 (40.9)	681 (43.9)	
12-17	321 (20.4)	7 (31.8)	314 (20.3)	
Median age, years (IQR)	6 (4-10)	10.5 (3.8 – 14.3)	6 (3.8 – 10)	0.045
Female sex, n (%)	684 (43.5)	11 (50)	877 (43.4)	0.54
Pre-existing conditions, n (%)				
Asthma	1377 (87.6)	20 (90.9)	1357 (87.5)	0.64
Requiring hospital admission	115 (7.3)	5 (22.7)	110 (7.1)	0.005
Requiring intensive care	63 (4)	1 (4.5)	62 (4)	0.89
Requiring intubation	19 (1.2)	1 (4.5)	18 (1.2)	0.15
With cardiac / respiratory arrest	5 (0.3)	0 (0)	5 (0.3)	0.79
Other respiratory illness				
Croup	94 (6)	1 (4.5)	93 (6)	0.78
Bronchiolitis	80 (5.1)	1 (4.5)	79 (5.1)	0.91
Pneumonia	44 (2.8)	1 (4.5)	43 (2.8)	0.62
Chest infection	32 (2)	1 (4.5)	31 (2)	0.40
Other	8 (0.5)	0 (0)	8 (0.5)	0.64
Initial physiological parameters				
Respiratory rate (breaths/minute), median (IQR)	32 (24 – 40)	35.5 (28 – 48.5)	32 (24 – 40)	0.09
Pulse rate (beats/minute), median (IQR)	130 (112 – 146)	134.5 (120 – 150.5)	130 (112 – 146)	0.24
Initial respiratory status, n (%)				
Normal	615 (39.1)	3 (13.6)	612 (39.5)	<0.001
Mild respiratory distress	363 (23.1)	1 (4.5)	362 (23.4)	
Moderate respiratory distress	315 (20)	2 (9.1)	313 (20.2)	
Severe respiratory distress	166 (10.6)	16 (72.7)	150 (9.7)	
Depressed respirations	1 (0.1)	0 (0)	1 (0.1)	
Final physiological parameters				

Respiratory rate (breaths/minute), median (IQR) †	28 (22 – 36)	28 (22 – 36)	30 (27 – 40)	0.06
Pulse rate (beats/minute), median (IQR) †	126 (108 – 142)	126 (108 – 142)	126 (112-162)	0.29
Final respiratory status, n (%)‡				
Normal	742 (56.8)	4 (18.2)	738 (57.4)	<0.001
Mild respiratory distress	400 (30.6)	4 (18.2)	396 (30.8)	
Moderate respiratory distress	127 (9.7)	6 (27.3)	121 (9.4)	
Severe respiratory distress	38 (2.9)	8 (36.4)	30 (2.4)	

All P values calculated using Chi-Square tests, except for continuous variables where Mann-Whitney U tests* were used.

† Data was not available for final pulse rate and respiratory rate for 54 patients in the “No escalation of care” group

‡ Data was not available for final respiratory status for 265 patients in the “No escalation of care” group

Table 2. Treatment provided by AV paramedics.

	Total (n=1572)	Escalation of care (n=22)	No escalation of care (n=1550)	P value (escalation vs no escalation)
Respiratory support, n(%)				
Bag-valve-mask applied	1 (0.1)	1 (4.5)	0 (0)	<0.001
Oxygen delivery				
Nasal cannulae	46 (2.9)	4 (18.2)	42 (2.7)	<0.001
Nebuliser mask	258 (16.4)	10 (45.5)	248 (16)	<0.001
Oxygen mask	48 (3.1)	0 (0)	48 (3.1)	0.40
Non-rebreather mask	8 (0.5)	0 (0)	8 (0.5)	0.74
Other oxygen therapy (not otherwise specified)	2 (0.1)	0 (0)	2 (0.1)	0.87
Parenteral bronchodilator				
Adrenaline IM injection	20 (1.3)	20 (90.9)	0 (0)	<0.001
Adrenaline infusion	4 (0.3)	4 (18.2)	0 (0)	<0.001
Dexamethasone				
IV injection	25 (1.6)	4 (18.2)	21 (1.4)	<0.001
Oral	141 (9)	11 (50)	130 (8.4)	<0.001
Inhaled bronchodilator				
Any inhaled bronchodilator	946 (60.2)	21 (95.5)	925 (59.7)	<0.001
Any Ipratropium bromide nebulisation	453 (28.8)	17 (77.3)	436 (28.1)	<0.001
Any Salbutamol pMDI	465 (29.6)	3 (13.6)	462 (29.8)	0.10
Any Salbutamol nebulisation	513 (32.6)	20 (90.9)	493 (31.8)	<0.001
Single administration of inhaled salbutamol	348 (22.1)	3 (13.6)	345 (22.3)	
Single administration of inhaled ipratropium bromide	13 (0.8)	1 (4.5)	12 (0.8)	
Single administration of inhaled salbutamol and single administration of inhaled ipratropium bromide	280 (17.8)	6 (27.3)	274 (17.7)	
Two administrations of inhaled salbutamol alone	114 (7.3)	1 (4.5)	113 (7.3)	
Two administrations of inhaled salbutamol and at	112 (7.1)	3 (13.6)	109 (7)	

least one administration of ipratropium bromide				
Three or more administrations of inhaled salbutamol alone	31 (2.0)	0 (0)	31 (2)	
Three or more administrations of inhaled salbutamol and at least one administration of ipratropium bromide	48 (3.1)	7 (31.8)	41 (2.6)	
Total instances of inhaled bronchodilator administration, median (IQR)	1 (0-2)	2 (1.8 – 4)	1 (0 – 2)	<0.001
Intravenous access				
Intravenous access attempt	39 (2.5)	7 (31.8)	32 (2.1)	<0.001
Successful IV attempt	34 (2.2)	7 (31.8)	27 (1.7)	<0.001

No patients received any of: BIPAP, manual ventilation, mechanical ventilation, IV salbutamol infusion, IM dexamethasone.

Figure 2. Initial and final respiratory status documented by AV paramedics.

For peer review only

Note: 111 patients missing initial respiratory status, and 265 missing final respiratory status.

Contributorship statement

SC, CW and FEB identified the research question. SC and CLW were responsible for the study design and research protocol. BD and ZN obtained data and input into data cleaning and analysis. SC was responsible for statistical analysis. SC drafted the initial manuscript. SC, BD, ZN, CLW, SRD, GMN, CVEP, AG and FEB contributed equally to writing, reviewing and editing the manuscript.

All authors provided comments on the drafts and have read and approved the final version of the article. All authors has full access to all of the data (including statistical reports and tables) at the conclusion of the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

SC is the guarantor for the paper, accepts full responsibility for the work and/or the conduct of the study, had access to the data and controlled the decision to publish.

Competing interests

There are no competing interests for any author.

Funding

SC has received funding from a Thoracic Society of Australia and New Zealand / National Asthma Council Fellowship and the ACEM Foundation Al Spilman Early Career Research Grant 2017.

SRD's time is funded in part by Cure Kids New Zealand

FEB's time was part funded by a grant from the Royal Children's Hospital Foundation, Melbourne, Victoria, Australia; an NHMRC (National Health and Medical Research Council) Practitioner Fellowship; and an NHMRC Investigator Leadership Grant (GNT1171228).

ZN's time is part funded by a grant from the National Heart Foundation of Australia.

Data sharing statement

Data are available on reasonable request. De-identified participant data will be available for sharing from 1 July 2024. Any data access requests should be sent to SC (simon.craig@monash.edu), and should include a proposal from the individual or organisation regarding their plan for use of the data.

The study team will review the request and consider the scientific merit of the proposed use of the data, and the legal, regulatory and ethical issues pertinent to the request. Presuming all constraints are addressed, the data will be shared using a secure file transfer platform.

Ethical statement.

The project was approved by the Royal Children's Hospital Research Ethics and Governance Office, Melbourne, Australia (60707), and the Ambulance Victoria Research Governance Committee, Melbourne, Australia.

References

1. Alpern ER, Stanley RM, Gorelick MH, et al. Epidemiology of a pediatric emergency medicine research network: the PECARN Core Data Project. *Pediatric emergency care* 2006; **22**(10): 689-99.
2. Acworth J, Babl F, Borland M, et al. Patterns of presentation to the Australian and New Zealand Paediatric Emergency Research Network. *Emerg Med Australas* 2009; **21**(1): 59-66.
3. Weiss AJ, Wier LM, Stocks C, Blanchard J. Overview of Emergency Department Visits in the United States, 2011: Statistical Brief #174. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.
4. Nath JB, Hsia RY. Children's emergency department use for asthma, 2001-2010. *Academic pediatrics* 2015; **15**(2): 225-30.
5. Kantor DB, Phipatanakul W. Intravenous beta agonists and severe pediatric asthma exacerbation: time for a closer look at terbutaline? *Ann Allergy Asthma Immunol* 2014; **112**(3): 187.
6. Giordano K, Rodriguez E, Green N, et al. Pulmonary Function Tests in Emergency Department Pediatric Patients with Acute Wheezing/Asthma Exacerbation. *Pulmonary Medicine* 2012; **2012**: 724139.
7. Kelly AM, Kerr D, Powell C. Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma? *Respir Med* 2004; **98**(8): 777-81.
8. Powell CV, Kelly AM, Kerr D. Lack of agreement in classification of the severity of acute asthma between emergency physician assessment and classification using the National Asthma Council Australia guidelines (1998). *Emergency medicine (Fremantle, WA)* 2003; **15**(1): 49-53.
9. O'Connor MG, Saville BR, Hartert TV, Arnold DH. Treatment Variability of Asthma Exacerbations in a Pediatric Emergency Department Using a Severity-Based Management Protocol. *Clinical pediatrics* 2014; **53**(13): 1288-90.
10. Biagini Myers JM, Simmons JM, Kercksmar CM, et al. Heterogeneity in asthma care in a statewide collaborative: the Ohio Pediatric Asthma Repository. *Pediatrics* 2015; **135**(2): 271-9.
11. Morris I, Lyttle MD, O'Sullivan R, Sargant N, Doull IJ, Powell CV. Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland? *Thorax* 2015; **70**(1): 88-91.
12. Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. *BMJ Open Respir Res* 2022; **9**(1).
13. Monteverde-Fernandez N, Diaz-Rubio F, Vásquez-Hoyos P, Rotta AT, González-Dambrasuskas S. Variability in care for children with severe acute asthma in Latin America. *Pediatr Pulmonol* 2021; **56**(2): 384-91.
14. Kalburgi S, Halley T. High-Flow Nasal Cannula Use Outside of the ICU Setting. *Pediatrics* 2020; **146**(5).
15. Johnson MD, Zorc JJ, Nelson DS, et al. Intravenous Magnesium in Asthma Pharmacotherapy: Variability in Use in the PECARN Registry. *J Pediatr* 2020; **220**: 165-74.e2.


16. Craig SS, Dalziel SR, Powell CV, Graudins A, Babl FE, Lunny C. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2020; **8**: Cd012977.
17. Gray CS, Powell CVE, Babl FE, Dalziel SR, Craig S. Variability of outcome measures in trials of intravenous therapy in acute severe paediatric asthma: a systematic review. *Emerg Med J* 2019; **36**(4): 225-30.
18. Nassif A, Ostermayer DG, Hoang KB, Claiborne MK, Camp EA, Shah MI. Implementation of a Prehospital Protocol Change For Asthmatic Children. *Prehosp Emerg Care* 2018; **22**(4): 457-65.
19. Riney LC, Schwartz H, Murtagh Kurowski E, Collett L, Florin TA. Improving Administration of Prehospital Corticosteroids for Pediatric Asthma. *Pediatr Qual Saf* 2021; **6**(3): e410.
20. Cheetham AL, Navanandan N, Leonard J, Spaur K, Markowitz G, Adalgais KM. Impact of prehospital pediatric asthma management protocol adherence on clinical outcomes. *J Asthma* 2022; **59**(5): 937-45.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; **147**(8): 573-7.
22. Ambulance Victoria. Clinical Practice Guidelines for Ambulance and MICA Paramedics. January 2018. Ambulance Victoria, Doncaster.
[Online resource: Available from: <https://www.ambulance.vic.gov.au/wp-content/uploads/2019/07/Clinical-Practice-Guidelines-2018-Edition-1.9-1.pdf> Accessed 15/9/2022].
23. Ambulance Victoria Annual report 2019-20. Ambulance Victoria, Melbourne. 2020.
[Online resource. Available from: <https://www.ambulance.vic.gov.au/about-us/our-performance/> Accessed 15/9/2022].
24. Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. *BMJ Open Respir Res.* 2022 Mar;9(1):e001137. .
25. Hasegawa K, Craig SS, Teach SJ, Camargo CA Jr. Management of Asthma Exacerbations in the Emergency Department. *J Allergy Clin Immunol Pract.* 2020 Dec 31:S2213-2198(20)31399-4. .
26. Pfeiffer CK, Smith K, Bernard S, et al. Prehospital benzodiazepine use and need for respiratory support in paediatric seizures. *Emerg Med J* 2022; **39**(8): 608-15.
27. Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta DC, Steiner J. Chart reviews in emergency medicine research: Where are the methods? *Ann Emerg Med* 1996; **27**(3): 305-8.
28. Kaji AH, Schriger D, Green S. Looking through the retrospectroscope: reducing bias in emergency medicine chart review studies. *Ann Emerg Med* 2014; **64**(3): 292-8.

Supplementary Online Table

Administration of asthma treatment according to initial respiratory status


	Normal respiratory status or mild respiratory distress (n=978)	Moderate respiratory distress (n=315)	Severe respiratory distress or Depressed respirations (n=167)
Salbutamol (pMDI)			
n (%)	314 (32.1)	111 (35.2)	15 (9.0)
Median (IQR)	0 (0 – 1)	0 (0 – 1)	0 (0 – 0)
Salbutamol (nebuliser)			
n (%)	155 (15.8)	182 (57.8)	151 (90.4)
Median (IQR)	0 (0 – 0)	1 (0 – 1)	1 (1 – 2)
Any salbutamol			
n (%)	455 (46.5)	274 (87.0)	157 (94.0)
Median (IQR)	0 (0 – 0)	1 (0 – 1)	1 (1 – 2)
Ipratropium, n (%)			
n (%)	125 (12.8)	164 (52.1)	144 (86.2)
Median (IQR)	0 (0 – 0)	1 (0 – 1)	1 (1 – 1)
Dexamethasone (any route)			
Any route, n (%)	41 (4.2)	56 (17.8)	58 (34.8)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



152x205mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1328x1387mm (72 x 72 DPI)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract YES – see title.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Structured abstract provided
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 7
Objectives	3	State specific objectives, including any prespecified hypotheses Page 8
Methods		
Study design	4	Present key elements of study design early in the paper Page 8 – (“study design” section)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 8-9 (“study setting” section)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case Page 9 (“selection of participants” section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 9-10 (“data collection” section)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 9-10 (“data collection” section)
Bias	9	Describe any efforts to address potential sources of bias Page 10 (end of “data collection” section)
Study size	10	Explain how the study size was arrived at Page 10 (“analysis” section)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 10 (“analysis” section)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i>—If applicable, explain how loss to follow-up was addressed <i>Case-control study</i>—If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i>—If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p> <p>Page 10 (“analysis” section)</p>
Results		
Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 10-11 (“results” section)</p> <p>(b) Give reasons for non-participation at each stage Page 10-11 (“results” section)</p> <p>(c) Consider use of a flow diagram – See figure 1</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 10-11 (“results” section) and table 1</p> <p>(b) Indicate number of participants with missing data for each variable of interest Not applicable (no missing data) Missing data indicated in Table 1, and mentioned in limitations section</p> <p>(c) <i>Cohort study</i>—Summarise follow-up time (eg, average and total amount) Not applicable (no patient follow-up)</p>
Outcome data	15*	<p><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</p> <p><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</p> <p><i>Cross-sectional study</i>—Report numbers of outcome events or summary measures Table 2, Figure 2 and results (page 10-12)</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Table 2, Figure 2 and results (page 10-12)</p>
Other analyses	17	<p>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</p> <p>Not applicable. No subgroup analyses performed</p>
Discussion		
Key results	18	<p>Summarise key results with reference to study objectives Page 13-14</p>
Limitations	19	<p>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 14-15</p>

1		
2		
3		
4	Interpretation	20
5		
6		
7	Generalisability	21
8		
9		
10	Other information	
11	Funding	22
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract YES – see title.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Structured abstract provided
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 7
Objectives	3	State specific objectives, including any prespecified hypotheses Page 8
Methods		
Study design	4	Present key elements of study design early in the paper Page 8 – (“study design” section)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 8-9 (“study setting” section)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case Page 9 (“selection of participants” section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 9-10 (“data collection” section)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 9-10 (“data collection” section)
Bias	9	Describe any efforts to address potential sources of bias Page 10 (end of “data collection” section)
Study size	10	Explain how the study size was arrived at Page 10 (“analysis” section)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 10 (“analysis” section)

Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i>—If applicable, explain how loss to follow-up was addressed</p> <p><i>Case-control study</i>—If applicable, explain how matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i>—If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p> <p>Page 10 (“analysis” section)</p>
Results		
Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 10-11 (“results” section)</p> <p>(b) Give reasons for non-participation at each stage Page 10-11 (“results” section)</p> <p>(c) Consider use of a flow diagram – See figure 1</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <p>Page 10-11 (“results” section) and table 1</p> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>Missing data indicated in Table 1, and mentioned in limitations section</p> <p>(c) <i>Cohort study</i>—Summarise follow-up time (eg, average and total amount)</p> <p>Not applicable (no patient follow-up)</p>
Outcome data	15*	<p><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</p> <p><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</p> <p><i>Cross-sectional study</i>—Report numbers of outcome events or summary measures</p> <p>Table 2, Figure 2 and results (page 10-12)</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p> <p>Table 2, Figure 2 and results (page 10-12)</p>
Other analyses	17	<p>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</p> <p>Not applicable. No subgroup analyses performed</p>
Discussion		
Key results	18	<p>Summarise key results with reference to study objectives</p> <p>Page 13-14</p>
Limitations	19	<p>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</p> <p>Page 14-15</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
----------------	----	--

Page 13-15

Generalisability	21	Discuss the generalisability (external validity) of the study results
------------------	----	---

Page 13-15

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
---------	----	---

Funding disclosures provided

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Acute paediatric asthma treatment in the pre-hospital setting: a retrospective observational study.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-073029.R2
Article Type:	Original research
Date Submitted by the Author:	25-May-2023
Complete List of Authors:	Craig, Simon; Monash Medical Centre Clayton, Paediatric Emergency Department; Monash University Department of Paediatrics Delardes, Belinda; Ambulance Victoria; Monash University Department of Paramedicine Nehme, Ziad; Ambulance Victoria, Research & Evaluation; Monash University School of Public Health and Preventive Medicine Wilson, Catherine; Murdoch Childrens Research Institute, Emergency Medicine Research Group; PREDICT, Research Group Dalziel, Stuart; Starship Children's Health, Emergency Department; The University of Auckland Faculty of Medical and Health Sciences, Paediatrics and Surgery Nixon, Gillian; Monash University Department of Paediatrics; Monash Children's Hospital, Respiratory Medicine Powell, Colin; Sidra Medical and Research Center, Department of Emergency Medicine; Cardiff School of Health Sciences Graudins, Andis; Monash Health, Dandenong Emergency Department; Monash University Babl, Franz; Royal Childrens Hospital, Emergency Department; The University of Melbourne Faculty of Medicine Dentistry and Health Sciences, Paediatrics
Primary Subject Heading:	Paediatrics
Secondary Subject Heading:	Emergency medicine
Keywords:	Asthma < THORACIC MEDICINE, ACCIDENT & EMERGENCY MEDICINE, Paediatric A&E and ambulatory care < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Acute paediatric asthma treatment in the pre-hospital setting: a retrospective**
4 **observational study.**
5
6
7
8
9

10 **Simon Craig**^{1,2,3} MBBS FACEM MPH MHPE, **Belinda Delardes**^{4,5} B Paramedic (Hons), **Ziad**
11 **Nehme**^{4,5,6} PhD, **Catherine L Wilson**³ Dip App Sci Nurs MPH Ms Evaluation and Assessment,
12 **Stuart R Dalziel**^{7,8} MBChB FRACP PhD, **Gillian M Nixon**^{1,9} MBChB MD FRACP, **Colin VE**
13 **Powell**^{10,11} MBChB DCH MRCP(UK) FRACP FRCPC MD, **Andis Gaudins**^{12,13,14} MBBS PhD
14 FACEM FACMT, **Franz E Babi**^{3,15,16,17} MD MPH DMedSc FRACP FAAP FACEP on behalf of the
15 PREDICT Network.
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 **Affiliations**
31

- 32 1. Department of Paediatrics, School of Clinical Sciences at Monash Health, Monash
33 University, Victoria, Australia.
- 34 2. Monash Emergency Program, Paediatric Emergency Department, Monash Medical
35 Centre, Monash Health, Victoria, Australia.
- 36 3. Emergency Research, Clinical Sciences, Murdoch Children's Research Institute,
37 Victoria, Australia
- 38 4. Ambulance Victoria, Blackburn North, Victoria, Australia
- 39 5. Department of Paramedicine, Monash University, Frankston, Victoria, Australia
- 40 6. School of Public Health and Preventive Medicine, Monash University, Melbourne,
41 Victoria, Australia
- 42 7. Departments of Surgery and Paediatrics: Child and Youth Health, The University of
43 Auckland, New Zealand.
- 44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
8. Children's Emergency Department, Starship Children's Hospital, Auckland, New Zealand
9. Department of Respiratory Medicine, Monash Children's Hospital, Melbourne, Victoria, Australia.
10. Division of Population Medicine, School of Medicine, Cardiff, United Kingdom.
11. Emergency Medicine, Sidra Medicine, Doha Qatar
12. Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Victoria, Australia.
13. Monash Emergency Program, Monash Health, Dandenong Hospital, Victoria, Australia.
14. Monash Health Clinical Toxicology and Addiction Medicine Service, Monash Health, Dandenong Hospital, Victoria, Australia.
15. Department of Emergency Medicine, The Royal Children's Hospital, Victoria, Australia.
16. Department of Paediatrics, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.
17. Department of Critical Care, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria, Australia.

Abstract 238 words (max 300)

Main text 2398 words (max 3000)

27 references (max 30)

2 tables, 2 figures, 1 box (up to 6 total). One supplementary online table.

1
2
3
4
5
6
7
8
9
10 Corresponding author
11
12

13 Prof Simon Craig
14

- 15 - Paediatric Emergency Department, Monash Medical Centre, Monash Health, Clayton,
16
17 Victoria, Australia
18
- 19 - Department of Paediatrics, Monash University, Clayton, Victoria, Australia
20
21

22 Simon.Craig@monash.edu
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Objectives:** To describe the incidence of and patterns of “escalated care” (care in addition to
4 standard treatment with systemic corticosteroids and inhaled bronchodilators) for children
5 receiving pre-hospital treatment for asthma.
6
7
8
9

10
11
12
13 **Design:** Retrospective observational study
14
15
16

17
18 **Setting:** State-wide ambulance service data (Ambulance Victoria in Victoria, Australia,
19 population 6.5 million)
20
21
22

23
24
25 **Participants:** Children aged 1-17 years and given a final diagnosis of asthma by the treating
26 paramedics and/or treated with inhaled bronchodilators from 1 July 2019 to 30 June 2020.
27
28
29

30
31
32 **Primary and secondary outcome measures:** We classified “escalation of care” as parenteral
33 administration of adrenaline, or provision of respiratory support. We compared clinical,
34 demographic and treatments administered between those receiving and not receiving
35 escalation of care.
36
37
38
39
40
41
42
43
44

45 **Results:** Paramedics attended 1,572 children with acute exacerbations of asthma during the
46 1-year study period. Of these, 22 (1.4%) had escalated care, all receiving parenteral
47 adrenaline. Patients with escalated care were more likely to be older, had previously required
48 hospital admission for asthma and had severe respiratory distress at initial assessment.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Of 1307 children with respiratory status data available, at arrival to hospital the respiratory status of children had improved overall (normal/mild respiratory distress at initial assessment 847 (64.8%), normal/mild respiratory distress at hospital arrival 1142 (87.4%), $p < 0.0001$).

1
2
3
4
5
6 **Conclusions:** Most children with acute exacerbations of asthma did not receive escalated
7
8 therapy during their pre-hospital treatment from ambulance paramedics. Most patients were
9
10 treated with inhaled bronchodilators only and clinically improved by the time they arrived in
11
12 hospital.
13
14
15
16
17
18
19
20
21
22

23 **Strengths and limitations of this study**

- 24 - Highly generalisable, with the use of a comprehensive electronic state-wide
25 ambulance database.
26
- 27 - Most ambulance cases were concentrated in metropolitan regions; this may limit
28 generalisability to rural and regional settings.
29
- 30 - Bias was minimised by direct download from electronic medical record, rather than
31 abstraction by reviewers.
32
- 33 - It is possible that a small number of critically ill cases were misclassified due to an
34 ambulance diagnosis other than asthma.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

Asthma is a frequent reason for children to attend the emergency department (ED),^{1,2} and one of the most common reasons for paediatric hospitalization after an ED visit.³ In the USA, the rate of paediatric ED visits for asthma increased by 13.3% between 2001 and 2010,⁴ while in the United Kingdom, it is estimated that a child is admitted to hospital with an asthma attack every 20 minutes.⁵

Most children with asthma have mild or moderate exacerbations, and respond to first-line treatment with inhaled bronchodilator therapy and systemic steroids.⁶⁻⁹ However, some children with severe asthma require more intensive therapies including intravenous (IV) medications, endotracheal intubation and/or admission to intensive care.⁹⁻¹¹ Management of acute severe asthma is complicated by a number of problems, including a large number of treatment options, wide variation in self-reported and actual physician practice,¹²⁻¹⁵ and a weak evidence base.^{16,17}

Early initiation of therapy in the pre-hospital setting may abort an asthma attack and prevent further escalation on arrival to the ED. This in turn may prevent the need for more invasive treatment and potential complications or side effects of medications used in escalation. The introduction of a new treatment protocol emphasizing early use of systemic corticosteroids in a large Emergency Medical Services system was associated with reduced rates of hospitalization, less need for critical care and shortened hospital length of stay.¹⁸ Systemic corticosteroid administration has been the subject of successful improvement projects in the pre-hospital setting.¹⁹ However, a separate study identified high rates of paramedic non-compliance with pre-hospital treatment protocols recommending parenteral adrenaline for children with high-severity respiratory distress.²⁰

1
2
3 There are little data available on treatment patterns or pre-hospital outcomes for children
4 with acute asthma in the Australian setting. This study aimed to extract information from the
5 electronic medical records of Ambulance Victoria (AV), Australia, on all children treated for
6 asthma to understand the incidence of and patterns of “escalated” care (care in addition to
7 standard treatment with systemic corticosteroids and inhaled bronchodilators).
8
9
10
11
12
13
14
15
16
17

18 **Methods**

19 ***Study design***

20 This was a retrospective cohort study of all children who were either given a final diagnosis
21 of asthma by the treating AV paramedics or treated with inhaled bronchodilators from 1 July
22 2019 to 30 June 2020. The project is reported according to the Strengthening the Reporting
23 of Observational Studies in Epidemiology (STROBE) statement.²¹ The study was approved by
24 the Royal Children’s Hospital Research Ethics and Governance Office, Melbourne, Australia
25 (60707) and the Ambulance Victoria Research Governance Committee, Melbourne, Australia.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 ***Study setting***

41 AV is the single public emergency medical service for the state of Victoria, Australia
42 (population of 6.5 million over 227,000 square kilometres).
43
44

45 AV clinical practice guidelines²² provide recommendations for asthma management according
46 to severity (Box 1), which include: inhaled salbutamol via a pressurised metered dose inhaler
47 (pMDI) as initial treatment for mild / moderate asthma; nebulised salbutamol and
48 ipratropium reserved for severe or critical illness, or failure of moderate asthma to respond
49 to treatment after 20 minutes; corticosteroids (intravenous or oral dexamethasone) for
50 critical asthma in children and for severe and critical asthma in adults; parenteral adrenaline
51
52
53
54
55
56
57
58
59
60

1
2
3 (intramuscular, intravenous infusion or titrated boluses) for critical asthma; and assisted
4
5 ventilation and/or intubation for unconsciousness or respiratory arrest. Children aged 12
6
7 years or more are managed according to an “adult” algorithm, which has a lower threshold
8
9 for corticosteroids compared to the paediatric algorithm (recommended for all severe cases,
10
11 rather than only in critical illness) .²²
12
13
14
15
16
17

18 ***Selection of participants.***

19
20 We searched the AV electronic patient care system for presentations of children aged more
21
22 than one year and less than 18 years matching the following criteria: final primary assessment
23
24 of asthma or cough or shortness of breath. We excluded children with a paramedic diagnosis
25
26 of cough or shortness of breath if they were not administered any inhaled bronchodilator
27
28 (salbutamol or ipratropium). Records of cases assessed by multiple ambulance teams during
29
30 the same incident were unified as a single paramedic attendance. Interhospital transports
31
32 and patients managed for cardiac arrest were excluded.
33
34
35
36
37
38
39

40 ***Data collection***

41
42 Data were extracted directly from the AV medical record database into a purpose-designed
43
44 spreadsheet and analysed. Exact medication doses were not extracted, as treatment is highly
45
46 protocolised (Box 1).
47
48

49 We defined “respiratory support” as the use of continuous positive airway pressure (CPAP),
50
51 bi-level positive airway pressure (BiPAP), assisted ventilation, intubation and mechanical
52
53 ventilation, or application of a bag-valve-mask device.
54
55

56 We defined “escalation” of care as parenteral administration of adrenaline, or provision of
57
58 respiratory support. Although AV protocols recommend oral (or parenteral) corticosteroids
59
60

1
2
3 for severe and critical asthma, corticosteroids are usually considered part of routine asthma
4 care (rather than reserved for critical illness). We did not include nebulised adrenaline for
5 suspected croup / upper airway obstruction. The case notes were reviewed and verified by a
6 second paramedic abstractor (BD) for all patients where escalation was identified through
7 electronic medical record data.
8
9
10
11
12
13
14
15
16
17

18 ***Analysis***

19
20 Descriptive statistics were used to summarise patient characteristics, clinical features and
21 treatments administered. Non-parametric data is reported using median and interquartile
22 range (IQR), while categorical data is presented as count and percentage. We did not impute
23 any missing data.
24
25
26
27
28

29
30 Comparisons were made between those requiring escalation of care to those not requiring
31 escalation of care. Categorical data is compared using Chi-square test or Fisher's exact test as
32 appropriate. Non-parametric data is compared using Mann-Whitney U test.
33
34
35
36

37 All analyses were performed using SPSS for Windows (IBM Corp. Released 2021. IBM SPSS
38 Statistics for Windows, Version 28.0. Armonk, NY: IBM Corp.).
39
40
41
42
43
44

45 ***Patient and public involvement***

46
47 Patients were not involved in the design of this study.
48
49
50
51

52 **Results**

53
54 Over the study period, the service responded to 633,950 on-road emergency cases,²³ mainly
55 using advanced life support (ALS) or mobile intensive care ambulance (MICA) paramedics. We
56 identified 3,587 children who had been assessed by AV with a primary assessment diagnosis
57
58
59
60

1
2
3 of asthma, cough, or shortness of breath, 1,520 were excluded, leaving 1,572 children
4 managed by AV with asthma (figure 1).
5
6

7
8 The median age of the cohort was 6 years (IQR 4-10 years) and 888 (56.5%) were male. Most
9
10 (87.6%) patients had a documented past history of asthma, 115 (7.3%) had been hospitalised,
11
12 63 (4%) had required intensive care admission, and 19 (1.2%) had been intubated for a
13
14 previous asthma exacerbation. Information on usual asthma medications was not available.
15
16 The median initial respiratory rate was 32 breaths/minute (IQR 24 – 40 breaths/minute). Of
17
18 the 1,460 patients who had initial work of breathing documented, 978 (67.0%) had normal or
19
20 mild work of breathing, and 166 (7.7%) had severe work of breathing.
21
22
23

24
25 Ambulance response time was a median of 11.9 minutes (IQR 8.2 to 15.2 minutes);
26
27 paramedics were on the scene with the patient for a median of 17 minutes (IQR 12.7 to 25.1
28
29 minutes). Patients were transported by ambulance in 90% (n=1419) of attendances.
30
31

32
33 Paramedics administered inhaled bronchodilators in 946 (60.2%) of cases. Of those, 493
34
35 (52.1%) received salbutamol alone, 13 (1.4%) received ipratropium alone, and 440 (46.5%)
36
37 received salbutamol and ipratropium. For those receiving bronchodilators, a median (IQR) of
38
39 1 (1-2) administrations were recorded. Oxygen administration was documented in 306
40
41 (19.4%) patients, most commonly by nebuliser mask, nasal cannulae, or an oxygen mask;
42
43 however, 514 (32.6%) received nebulised medication, driven by oxygen. Oral corticosteroids
44
45 were administered to 141 (9.0%) patients.
46
47
48

49
50 Twenty-six records were reviewed for escalation of care; in four patients the electronic record
51
52 was incorrectly coded, due to inadvertent selection of intravenous salbutamol (used by AV
53
54 for pre-term labour) instead of nebulised salbutamol, leaving 22 (1.4%) patients with
55
56 escalated care (figure 1). Patients with escalated care were more likely to be older, had
57
58 previously required hospital admission for asthma and had severe respiratory distress at
59
60

1
2
3 initial assessment (Table 1). Those receiving escalated care were more likely to be treated
4
5 with inhaled bronchodilators, corticosteroids and oxygen (Table 2). With increasing severity
6
7 of illness, children were more likely to be administered nebulised salbutamol, less likely to be
8
9 administered salbutamol by a pMDI, more likely to receive ipratropium and more likely to
10
11 receive systemic corticosteroids (Supplementary Online Table).
12
13

14
15 All patients who received escalated care received parenteral adrenaline. No patients received
16
17 non-invasive ventilation, assisted ventilation or intubation. Four children (aged two, fourteen,
18
19 sixteen and seventeen years) received an adrenaline infusion. One patient who received IM
20
21 adrenaline also had a bag-valve-mask applied, however, did not receive positive pressure
22
23 ventilation. They were a two-year-old child who had difficulty breathing and cough that was
24
25 not improving with salbutamol administered at home. They became unresponsive after a
26
27 coughing episode and bystander cardiopulmonary resuscitation was initiated. They were
28
29 breathing spontaneously and responsive upon initial paramedic assessment.
30
31
32
33

34
35 Reports of respiratory status at initial assessment and hospital arrival were available for 1307
36
37 (85.5%) of the cohort. On arrival to hospital the respiratory status of children had improved
38
39 overall (normal/mild respiratory distress at initial assessment 847 (64.8%), normal/mild
40
41 respiratory distress at hospital arrival 1142 (87.4%), $p < 0.0001$). One hundred and thirty-one
42
43 (81.2%) of the 160 children with severe respiratory distress at initial assessment had
44
45 improved. Of the 847 children with normal/mild respiratory distress at initial assessment, only
46
47 24 (2.8%) were documented as having moderate or severe respiratory distress at hospital
48
49 arrival; and only 9 (0.8%) of the 1146 children with normal/mild/moderate respiratory
50
51 distress at initial assessment were documented as having severe respiratory distress at
52
53 hospital arrival (Figure 2).
54
55
56
57
58
59
60

Discussion.

This study provides a population-based state-wide assessment of pre-hospital asthma management in children. Most children with acute exacerbations of asthma in Victoria, Australia, did not receive escalated therapy during their pre-hospital treatment from ambulance paramedics. Although more than 60% had either mild or no respiratory distress, over 90% of all patients were transported to hospital. Overall, the respiratory status of children improved from ambulance arrival to hospital arrival in all severity categories.

The overall rate of parenteral bronchodilator (adrenaline) administration was 1.6%. No patients received non-invasive ventilation, assisted ventilation or intubation, and most patients were treated with inhaled bronchodilators and clinically improved by the time they arrived in hospital. Those receiving escalated care were older, were more likely to have a history of asthma requiring hospital admission and/or intubation and have severe respiratory distress on ambulance arrival.

A recent large study described in-hospital management of acute asthma exacerbations in Australia and New Zealand. In 14,029 children, there was a higher overall rates of escalated therapy (7.3% overall, with 4.2% receiving parenteral bronchodilators and 4.3% respiratory support).²⁴ A common indication for escalation of care is failure to adequately respond to first-line therapy. The relatively low rates of treatment escalation in the pre-hospital setting (1.6%) suggests that a small proportion of children are seriously ill, while most are early in their treatment, and may not have had sufficient time to demonstrate improvement (or lack of improvement) prior to hospital arrival.

There is little evidence to guide escalated therapy for asthma. A recent Overview of Cochrane reviews of clinical trials on escalated therapy for asthma¹⁶ assessed the evidence for parenteral bronchodilators, Heliox, respiratory support and inhaled magnesium. The review

1
2
3 found that the majority of comparisons involved between one and three trials and fewer than
4
5 100 participants, making it difficult to assess the balance between benefits and potential
6
7 harms. The authors were unable to make firm practice recommendations.¹⁶
8
9

10 There is little evidence to support intramuscular adrenaline as first-line treatment for
11
12 seriously ill children with asthma,²⁵ although it has a number of advantages, including ease of
13
14 administration and paramedic familiarity. Parenteral adrenaline is also used for anaphylaxis,
15
16 cardiac arrest, and management of hypotension, while nebulised adrenaline is used for severe
17
18 upper airway obstruction in croup. In addition, it can be easily and rapidly administered as
19
20 there is no need for dilution prior to administration, and no requirement for a prolonged
21
22 infusion.²²
23
24
25
26

27 Pre-hospital treatment of asthma rarely results in escalation of therapy beyond inhaled
28
29 bronchodilators and systemic corticosteroids. In addition, the use of parenteral
30
31 bronchodilators is often reserved for those who do not improve after initial inhaled
32
33 bronchodilators, and is administered relatively late in the course of an ED visit.¹⁵ Given that
34
35 most children with asthma will improve with pre-hospital treatment, and/or will not have
36
37 sufficient time to “fail to improve” with standard therapy, it appears that any comparative
38
39 clinical trials to determine the superiority of one parenteral bronchodilator over another
40
41 should be reserved for the in-hospital rather than pre-hospital setting.
42
43
44
45
46
47
48
49

50 **Limitations**

51
52 Inclusion in the study was based on a combination of paramedic diagnosis of asthma and
53
54 administration of inhaled bronchodilators. While only 89% had a diagnosis of asthma
55
56 recorded in the ambulance notes, it seems that the cohort is reflective of the asthma
57
58 population as over 87% of cases had a previous diagnosis of asthma.
59
60

1
2
3 Due to state-wide data collection and large numbers of patients, our study is likely to be
4 generalisable to other settings with similar pre-hospital care systems. However, most
5
6 ambulance cases within Victoria are concentrated in the metropolitan area of Melbourne (the
7
8 capital city), which may limit generalisability to rural and regional settings. Approximately 10%
9
10 of children were not transported to hospital; this is similar to the rate identified in a study of
11
12 children with seizures from the same ambulance service.²⁶
13
14
15
16

17
18 This study is a retrospective review of a comprehensive electronic database. We optimised
19
20 data extraction and minimised bias through the collection of variables using a piloted data
21
22 collection instrument, and application of pre-defined inclusion and exclusion criteria.^{27,28} Due
23
24 to the nature of record-keeping within the ambulance service (all cases are documented using
25
26 the electronic system), it is unlikely that any cases of escalated care were missed. As we
27
28 downloaded fields directly from the electronic medical record system, we did not
29
30 independently abstract any variables. However, we verified all instances of documented
31
32 escalation of care through consultation with a second (paramedic) reviewer and identified
33
34 four cases of misclassification. It is possible that we missed some children who were not
35
36 classified as asthma, were critically ill, not given inhaled bronchodilators and only given
37
38 parenteral adrenaline. However, this is likely to be a very small number of cases. There was
39
40 some missing data on final observations on arrival to hospital, however, this was not a primary
41
42 objective of our study.
43
44
45
46
47
48
49
50
51

52 **Conclusions**

53
54 Most children with acute exacerbations of asthma did not receive escalated therapy during
55
56 their pre-hospital treatment from ambulance paramedics. Most patients were treated with
57
58 inhaled bronchodilators only and clinically improved by the time they arrived in hospital. Due
59
60

1
2
3 to the very low incidence of treatment escalation or clinical deterioration, any comparative
4
5 clinical trials to determine the superiority of one parenteral bronchodilator over another
6
7
8 should be reserved for the in-hospital rather than pre-hospital setting.
9
10
11
12
13
14

15 **Funding**

16
17
18 This work is supported by the NHMRC Centre of Research Excellence in Paediatric Emergency
19
20 Medicine (GNT1171228), Canberra, Australia. SC's contribution was funded by the Thoracic
21
22 Society of Australia and New Zealand and National Asthma Council Fellowship, 2020 and the
23
24 Australasian College for Emergency Medicine Foundation Al Spilman Early Career Research
25
26 Grant 2017. SRDs time was in part funded by Cure Kids New Zealand. FEB's time was funded
27
28 by an NHMRC Investigator Leadership grant and the Royal Children's Hospital Foundation,
29
30 Parkville, Australia.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 Figure 1. Flow chart – pre-hospital management of acute asthma in children.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

AV, Ambulance Victoria.

For peer review only

1
2
3
4
5
6
7
8 **Box 1.** Asthma severity assessment and treatment according to Ambulance Victoria Clinical
9 Practice Guidelines
10

11
12 **Mild / Moderate:** normal conscious state, some increased work of breathing, tachycardia,
13 speaking in phrases / sentences
14

- 15 - Salbutamol pMDI and spacer:
16 ○ 6 or more years: 4-12 doses
17 ○ 2-5 years: 2-6 doses
18
19

20
21 **Severe:** agitated / distressed, markedly increased work of breathing, including accessory
22 muscle use / retraction, tachycardia, speaking in words.
23

- 24 - Salbutamol nebulised (repeated at 20 minutes if required)
25 ○ 2-4 years: 2.5 mg
26 ○ 5-11 years: 2.5 - 5 mg
27
28 - Ipratropium bromide nebulised 250 mcg
29

30
31 **Critical:** altered conscious state, maximal work of breathing, marked tachycardia, unable to
32 talk.
33

- 34 - Salbutamol nebulised 10 mg (repeated at 5 minutes if required)
35 - Ipratropium bromide nebulised 250 mcg
36 - Adrenaline 10 mcg/kg IM (repeated at 5 minutes if required)
37 - Dexamethasone 0.6 mg/kg IV or oral (max 12 mg)
38 - Adrenaline IV boluses and infusion (for Mobile Intensive Care Paramedics)
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Demographics and clinical characteristics of children treated or assessed for asthma by AV.

	Total (n=1572)	Escalation of care (n=22)	No escalation of care (n=1550)	P value (escalation vs no escalation)
Age, years, n (%)				
1-4	561 (36.3)	6 (27.3)	555 (35.8)	0.38
5-11	690 (43.9)	9 (40.9)	681 (43.9)	
12-17	321 (20.4)	7 (31.8)	314 (20.3)	
Median age, years (IQR)	6 (4-10)	10.5 (3.8 – 14.3)	6 (3.8 – 10)	0.045
Female sex, n (%)	684 (43.5)	11 (50)	877 (43.4)	0.54
Pre-existing conditions, n (%)				
Asthma	1377 (87.6)	20 (90.9)	1357 (87.5)	0.64
Requiring hospital admission	115 (7.3)	5 (22.7)	110 (7.1)	0.005
Requiring intensive care	63 (4)	1 (4.5)	62 (4)	0.89
Requiring intubation	19 (1.2)	1 (4.5)	18 (1.2)	0.15
With cardiac / respiratory arrest	5 (0.3)	0 (0)	5 (0.3)	0.79
Other respiratory illness				
Croup	94 (6)	1 (4.5)	93 (6)	0.78
Bronchiolitis	80 (5.1)	1 (4.5)	79 (5.1)	0.91
Pneumonia	44 (2.8)	1 (4.5)	43 (2.8)	0.62
Chest infection	32 (2)	1 (4.5)	31 (2)	0.40
Other	8 (0.5)	0 (0)	8 (0.5)	0.64
Initial physiological parameters				
Respiratory rate (breaths/minute), median (IQR)	32 (24 – 40)	35.5 (28 – 48.5)	32 (24 – 40)	0.09
Pulse rate (beats/minute), median (IQR)	130 (112 – 146)	134.5 (120 – 150.5)	130 (112 – 146)	0.24
Initial respiratory status, n (%)				
Normal	615 (39.1)	3 (13.6)	612 (39.5)	<0.001
Mild respiratory distress	363 (23.1)	1 (4.5)	362 (23.4)	
Moderate respiratory distress	315 (20)	2 (9.1)	313 (20.2)	
Severe respiratory distress	166 (10.6)	16 (72.7)	150 (9.7)	
Depressed respirations	1 (0.1)	0 (0)	1 (0.1)	
Final physiological parameters				

Respiratory rate (breaths/minute), median (IQR) †	28 (22 – 36)	28 (22 – 36)	30 (27 – 40)	0.06
Pulse rate (beats/minute), median (IQR) †	126 (108 – 142)	126 (108 – 142)	126 (112– 162)	0.29
Final respiratory status, n (%)‡				
Normal	742 (56.8)	4 (18.2)	738 (57.4)	<0.001
Mild respiratory distress	400 (30.6)	4 (18.2)	396 (30.8)	
Moderate respiratory distress	127 (9.7)	6 (27.3)	121 (9.4)	
Severe respiratory distress	38 (2.9)	8 (36.4)	30 (2.4)	

All P values calculated using Chi-Square tests, except for continuous variables where Mann-Whitney U tests* were used.

† Data was not available for final pulse rate and respiratory rate for 54 patients in the “No escalation of care” group

‡ Data was not available for final respiratory status for 265 patients in the “No escalation of care” group

Table 2. Treatment provided by AV paramedics.

	Total (n=1572)	Escalation of care (n=22)	No escalation of care (n=1550)	P value (escalation vs no escalation)
Respiratory support, n(%)				
Bag-valve-mask applied	1 (0.1)	1 (4.5)	0 (0)	<0.001
Oxygen delivery				
Nasal cannulae	46 (2.9)	4 (18.2)	42 (2.7)	<0.001
Nebuliser mask	258 (16.4)	10 (45.5)	248 (16)	<0.001
Oxygen mask	48 (3.1)	0 (0)	48 (3.1)	0.40
Non-rebreather mask	8 (0.5)	0 (0)	8 (0.5)	0.74
Other oxygen therapy (not otherwise specified)	2 (0.1)	0 (0)	2 (0.1)	0.87
Parenteral bronchodilator				
Adrenaline IM injection	20 (1.3)	20 (90.9)	0 (0)	<0.001
Adrenaline infusion	4 (0.3)	4 (18.2)	0 (0)	<0.001
Dexamethasone				
IV injection	25 (1.6)	4 (18.2)	21 (1.4)	<0.001
Oral	141 (9)	11 (50)	130 (8.4)	<0.001
Inhaled bronchodilator				
Any inhaled bronchodilator	946 (60.2)	21 (95.5)	925 (59.7)	<0.001
Any Ipratropium bromide nebulisation	453 (28.8)	17 (77.3)	436 (28.1)	<0.001
Any Salbutamol pMDI	465 (29.6)	3 (13.6)	462 (29.8)	0.10
Any Salbutamol nebulisation	513 (32.6)	20 (90.9)	493 (31.8)	<0.001
Single administration of inhaled salbutamol	348 (22.1)	3 (13.6)	345 (22.3)	
Single administration of inhaled ipratropium bromide	13 (0.8)	1 (4.5)	12 (0.8)	
Single administration of inhaled salbutamol and single administration of inhaled ipratropium bromide	280 (17.8)	6 (27.3)	274 (17.7)	
Two administrations of inhaled salbutamol alone	114 (7.3)	1 (4.5)	113 (7.3)	
Two administrations of inhaled salbutamol and at	112 (7.1)	3 (13.6)	109 (7)	

least one administration of ipratropium bromide				
Three or more administrations of inhaled salbutamol alone	31 (2.0)	0 (0)	31 (2)	
Three or more administrations of inhaled salbutamol and at least one administration of ipratropium bromide	48 (3.1)	7 (31.8)	41 (2.6)	
Total instances of inhaled bronchodilator administration, median (IQR)	1 (0-2)	2 (1.8 – 4)	1 (0 – 2)	<0.001
Intravenous access				
Intravenous access attempt	39 (2.5)	7 (31.8)	32 (2.1)	<0.001
Successful IV attempt	34 (2.2)	7 (31.8)	27 (1.7)	<0.001

No patients received any of: BIPAP, manual ventilation, mechanical ventilation, IV salbutamol infusion, IM dexamethasone.

Figure 2. Initial and final respiratory status documented by AV paramedics.

For peer review only

Note: 111 patients missing initial respiratory status, and 265 missing final respiratory status.

Contributorship statement

SC, CW and FEB identified the research question. SC and CW were responsible for the study design and research protocol. BD and ZN obtained data and input into data cleaning and analysis. SC was responsible for statistical analysis. SC drafted the initial manuscript. SC, BD, ZN, CW, SRD, GMN, CVEP, AG and FEB contributed equally to writing, reviewing and editing the manuscript.

All authors provided comments on the drafts and have read and approved the final version of the article. All authors has full access to all of the data (including statistical reports and tables) at the conclusion of the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

SC is the guarantor for the paper, accepts full responsibility for the work and/or the conduct of the study, had access to the data and controlled the decision to publish.

Competing interests

There are no competing interests for any author.

Funding

SC has received funding from a Thoracic Society of Australia and New Zealand / National Asthma Council Fellowship and the ACEM Foundation Al Spilman Early Career Research Grant 2017.

SRD's time is funded in part by Cure Kids New Zealand

FEB's time was part funded by a grant from the Royal Children's Hospital Foundation, Melbourne, Victoria, Australia; an NHMRC (National Health and Medical Research Council) Practitioner Fellowship; and an NHMRC Investigator Leadership Grant (GNT1171228).

ZN's time is part funded by a grant from the National Heart Foundation of Australia.

Data sharing statement

Data are available on reasonable request. De-identified participant data will be available for sharing from 1 July 2024. Any data access requests should be sent to SC (simon.craig@monash.edu), and should include a proposal from the individual or organisation regarding their plan for use of the data.

The study team will review the request and consider the scientific merit of the proposed use of the data, and the legal, regulatory and ethical issues pertinent to the request. Presuming all constraints are addressed, the data will be shared using a secure file transfer platform.

Ethical statement.

The project was approved by the Royal Children's Hospital Research Ethics and Governance Office, Melbourne, Australia (60707), and the Ambulance Victoria Research Governance Committee, Melbourne, Australia.

References


1. Alpern ER, Stanley RM, Gorelick MH, et al. Epidemiology of a pediatric emergency medicine research network: the PECARN Core Data Project. *Pediatric emergency care* 2006; **22**(10): 689-99.
2. Acworth J, Babl F, Borland M, et al. Patterns of presentation to the Australian and New Zealand Paediatric Emergency Research Network. *Emerg Med Australas* 2009; **21**(1): 59-66.
3. Weiss AJ, Wier LM, Stocks C, Blanchard J. Overview of Emergency Department Visits in the United States, 2011: Statistical Brief #174. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.
4. Nath JB, Hsia RY. Children's emergency department use for asthma, 2001-2010. *Academic pediatrics* 2015; **15**(2): 225-30.
5. Kantor DB, Phipatanakul W. Intravenous beta agonists and severe pediatric asthma exacerbation: time for a closer look at terbutaline? *Ann Allergy Asthma Immunol* 2014; **112**(3): 187.
6. Giordano K, Rodriguez E, Green N, et al. Pulmonary Function Tests in Emergency Department Pediatric Patients with Acute Wheezing/Asthma Exacerbation. *Pulmonary Medicine* 2012; **2012**: 724139.
7. Kelly AM, Kerr D, Powell C. Is severity assessment after one hour of treatment better for predicting the need for admission in acute asthma? *Respir Med* 2004; **98**(8): 777-81.
8. Powell CV, Kelly AM, Kerr D. Lack of agreement in classification of the severity of acute asthma between emergency physician assessment and classification using the National Asthma Council Australia guidelines (1998). *Emergency medicine (Fremantle, WA)* 2003; **15**(1): 49-53.
9. O'Connor MG, Saville BR, Hartert TV, Arnold DH. Treatment Variability of Asthma Exacerbations in a Pediatric Emergency Department Using a Severity-Based Management Protocol. *Clinical pediatrics* 2014; **53**(13): 1288-90.
10. Biagini Myers JM, Simmons JM, Kercksmar CM, et al. Heterogeneity in asthma care in a statewide collaborative: the Ohio Pediatric Asthma Repository. *Pediatrics* 2015; **135**(2): 271-9.
11. Morris I, Lyttle MD, O'Sullivan R, Sargant N, Doull IJ, Powell CV. Which intravenous bronchodilators are being administered to children presenting with acute severe wheeze in the UK and Ireland? *Thorax* 2015; **70**(1): 88-91.
12. Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. *BMJ Open Respir Res* 2022; **9**(1).
13. Monteverde-Fernandez N, Diaz-Rubio F, Vásquez-Hoyos P, Rotta AT, González-Dambruskas S. Variability in care for children with severe acute asthma in Latin America. *Pediatr Pulmonol* 2021; **56**(2): 384-91.
14. Kalburgi S, Halley T. High-Flow Nasal Cannula Use Outside of the ICU Setting. *Pediatrics* 2020; **146**(5).
15. Johnson MD, Zorc JJ, Nelson DS, et al. Intravenous Magnesium in Asthma Pharmacotherapy: Variability in Use in the PECARN Registry. *J Pediatr* 2020; **220**: 165-74.e2.

16. Craig SS, Dalziel SR, Powell CV, Graudins A, Babl FE, Lunny C. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. *Cochrane Database Syst Rev* 2020; **8**: Cd012977.
17. Gray CS, Powell CVE, Babl FE, Dalziel SR, Craig S. Variability of outcome measures in trials of intravenous therapy in acute severe paediatric asthma: a systematic review. *Emerg Med J* 2019; **36**(4): 225-30.
18. Nassif A, Ostermayer DG, Hoang KB, Claiborne MK, Camp EA, Shah MI. Implementation of a Prehospital Protocol Change For Asthmatic Children. *Prehosp Emerg Care* 2018; **22**(4): 457-65.
19. Riney LC, Schwartz H, Murtagh Kurowski E, Collett L, Florin TA. Improving Administration of Prehospital Corticosteroids for Pediatric Asthma. *Pediatr Qual Saf* 2021; **6**(3): e410.
20. Cheetham AL, Navanandan N, Leonard J, Spaur K, Markowitz G, Adalgais KM. Impact of prehospital pediatric asthma management protocol adherence on clinical outcomes. *J Asthma* 2022; **59**(5): 937-45.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Ann Intern Med* 2007; **147**(8): 573-7.
22. Ambulance Victoria. Clinical Practice Guidelines for Ambulance and MICA Paramedics. January 2018. Ambulance Victoria, Doncaster.
[Online resource: Available from: <https://www.ambulance.vic.gov.au/wp-content/uploads/2019/07/Clinical-Practice-Guidelines-2018-Edition-1.9-1.pdf> Accessed 15/9/2022].
23. Ambulance Victoria Annual report 2019-20. Ambulance Victoria, Melbourne. 2020.
[Online resource. Available from: <https://www.ambulance.vic.gov.au/about-us/our-performance/> Accessed 15/9/2022].
24. Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: a Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. *BMJ Open Respir Res.* 2022 Mar;9(1):e001137. .
25. Hasegawa K, Craig SS, Teach SJ, Camargo CA Jr. Management of Asthma Exacerbations in the Emergency Department. *J Allergy Clin Immunol Pract.* 2020 Dec 31:S2213-2198(20)31399-4. .
26. Pfeiffer CK, Smith K, Bernard S, et al. Prehospital benzodiazepine use and need for respiratory support in paediatric seizures. *Emerg Med J* 2022; **39**(8): 608-15.
27. Gilbert EH, Lowenstein SR, Koziol-McLain J, Barta DC, Steiner J. Chart reviews in emergency medicine research: Where are the methods? *Ann Emerg Med* 1996; **27**(3): 305-8.
28. Kaji AH, Schriger D, Green S. Looking through the retrospectroscope: reducing bias in emergency medicine chart review studies. *Ann Emerg Med* 2014; **64**(3): 292-8.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



152x205mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1328x1387mm (72 x 72 DPI)

Supplementary Online Table

Administration of asthma treatment according to initial respiratory status

	Normal respiratory status or mild respiratory distress (n=978)	Moderate respiratory distress (n=315)	Severe respiratory distress or Depressed respirations (n=167)
Salbutamol (pMDI)			
n (%)	314 (32.1)	111 (35.2)	15 (9.0)
Median (IQR)	0 (0 – 1)	0 (0 – 1)	0 (0 – 0)
Salbutamol (nebuliser)			
n (%)	155 (15.8)	182 (57.8)	151 (90.4)
Median (IQR)	0 (0 – 0)	1 (0 – 1)	1 (1 – 2)
Any salbutamol			
n (%)	455 (46.5)	274 (87.0)	157 (94.0)
Median (IQR)	0 (0 – 0)	1 (0 – 1)	1 (1 – 2)
Ipratropium, n (%)			
n (%)	125 (12.8)	164 (52.1)	144 (86.2)
Median (IQR)	0 (0 – 0)	1 (0 – 1)	1 (1 – 1)
Dexamethasone (any route)			
Any route, n (%)	41 (4.2)	56 (17.8)	58 (34.8)

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract YES – see title.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Structured abstract provided
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 7
Objectives	3	State specific objectives, including any prespecified hypotheses Page 8
Methods		
Study design	4	Present key elements of study design early in the paper Page 8 – (“study design” section)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 8-9 (“study setting” section)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case Page 9 (“selection of participants” section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 9-10 (“data collection” section)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 9-10 (“data collection” section)
Bias	9	Describe any efforts to address potential sources of bias Page 10 (end of “data collection” section)
Study size	10	Explain how the study size was arrived at Page 10 (“analysis” section)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 10 (“analysis” section)

Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i>—If applicable, explain how loss to follow-up was addressed</p> <p><i>Case-control study</i>—If applicable, explain how matching of cases and controls was addressed</p> <p><i>Cross-sectional study</i>—If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p> <p>Page 10 (“analysis” section)</p>
Results		
Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 10-11 (“results” section)</p> <p>(b) Give reasons for non-participation at each stage Page 10-11 (“results” section)</p> <p>(c) Consider use of a flow diagram – See figure 1</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders</p> <p>Page 10-11 (“results” section) and table 1</p> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>Missing data indicated in Table 1, and mentioned in limitations section</p> <p>(c) <i>Cohort study</i>—Summarise follow-up time (eg, average and total amount)</p> <p>Not applicable (no patient follow-up)</p>
Outcome data	15*	<p><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</p> <p><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</p> <p><i>Cross-sectional study</i>—Report numbers of outcome events or summary measures</p> <p>Table 2, Figure 2 and results (page 10-12)</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period</p> <p>Table 2, Figure 2 and results (page 10-12)</p>
Other analyses	17	<p>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</p> <p>Not applicable. No subgroup analyses performed</p>
Discussion		
Key results	18	<p>Summarise key results with reference to study objectives</p> <p>Page 13-14</p>
Limitations	19	<p>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias</p> <p>Page 14-15</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Page 13-15
----------------	----	---

Generalisability	21	Discuss the generalisability (external validity) of the study results Page 13-15
------------------	----	--

Other information

Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Funding disclosures provided
---------	----	--

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract YES – see title.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Structured abstract provided
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Page 7
Objectives	3	State specific objectives, including any prespecified hypotheses Page 8
Methods		
Study design	4	Present key elements of study design early in the paper Page 8 – (“study design” section)
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Page 8-9 (“study setting” section)
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case Page 9 (“selection of participants” section)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Page 9-10 (“data collection” section)
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Page 9-10 (“data collection” section)
Bias	9	Describe any efforts to address potential sources of bias Page 10 (end of “data collection” section)
Study size	10	Explain how the study size was arrived at Page 10 (“analysis” section)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Page 10 (“analysis” section)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Statistical methods	12	<p>(a) Describe all statistical methods, including those used to control for confounding</p> <p>(b) Describe any methods used to examine subgroups and interactions</p> <p>(c) Explain how missing data were addressed</p> <p>(d) <i>Cohort study</i>—If applicable, explain how loss to follow-up was addressed <i>Case-control study</i>—If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i>—If applicable, describe analytical methods taking account of sampling strategy</p> <p>(e) Describe any sensitivity analyses</p> <p>Page 10 (“analysis” section)</p>
Results		
Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed Page 10-11 (“results” section)</p> <p>(b) Give reasons for non-participation at each stage Page 10-11 (“results” section)</p> <p>(c) Consider use of a flow diagram – See figure 1</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Page 10-11 (“results” section) and table 1</p> <p>(b) Indicate number of participants with missing data for each variable of interest Not applicable (no missing data) Missing data indicated in Table 1, and mentioned in limitations section</p> <p>(c) <i>Cohort study</i>—Summarise follow-up time (eg, average and total amount) Not applicable (no patient follow-up)</p>
Outcome data	15*	<p><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</p> <p><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</p> <p><i>Cross-sectional study</i>—Report numbers of outcome events or summary measures Table 2, Figure 2 and results (page 10-12)</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>(b) Report category boundaries when continuous variables were categorized</p> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Table 2, Figure 2 and results (page 10-12)</p>
Other analyses	17	<p>Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses</p> <p>Not applicable. No subgroup analyses performed</p>
Discussion		
Key results	18	<p>Summarise key results with reference to study objectives Page 13-14</p>
Limitations	19	<p>Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Page 14-15</p>

1		
2		
3	Interpretation	20
4		Give a cautious overall interpretation of results considering objectives, limitations,
5		multiplicity of analyses, results from similar studies, and other relevant evidence
6		Page 13-15
7	Generalisability	21
8		Discuss the generalisability (external validity) of the study results
9		Page 13-15
10	Other information	
11	Funding	22
12		Give the source of funding and the role of the funders for the present study and, if applicable,
13		for the original study on which the present article is based
14		Funding disclosures provided

15

16 *Give information separately for cases and controls in case-control studies and, if applicable, for exposed and

17 unexposed groups in cohort and cross-sectional studies.

18

19

20 **Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and

21 published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

22 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at

23 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is

24 available at www.strobe-statement.org.

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60